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ABSTRACT 
Prostaglandin F2α (PGF2α) is a potent physiological inhibitor of adipocyte 
differentiation, that has recently been shown to play an important role in the regulation of 
adipose tissue development in vivo, where it acts to oppose the development of obesity 
and its associated co-morbidities. Hence, it is of considerable interest to understand the 
underlying molecular mechanisms by which PGF2α inhibits adipogenesis. In this respect, 
previous studies from our laboratory have demonstrated that PGF2α inhibits 
adipogenesis via activation of the calcium/calmodulin-regulated, serine/threonine 
phosphatase, calcineurin. However, the precise molecular mechanism by which the 
PGF2α/calcineurin-signaling pathway inhibits adipogenesis is not known. Accordingly, 
the goal of this dissertation project was to identify the underlying molecular mechanisms 
by which this pathway inhibits adipocyte differentiation. Since the best known function 
of calcineurin is the regulation of gene expression, our central hypothesis was that 
calcineurin activation induces the expression of a gene(s) directly responsible for 
inhibiting adipogenesis. To test this hypothesis, we initially performed a microarray 
analysis to identify candidate calcineurin-regulated genes likely to be responsible. As a 
result of this analysis, we identified two excellent candidate genes that were strongly 
induced by PGF2α in a calcineurin-dependent fashion: the IL-11 cytokine and the Nurr1 
orphan nuclear hormone receptor. This dissertation describes our investigations into the 
xx 
 
potential roles of IL-11 and Nurr1 in mediating the inhibitory effects of the 
PGF2α/calcineurin-signaling pathway on adipogenesis.  
Initially, we demonstrate that activation of the PGF2α/calcineurin signaling 
pathway in differentiating 3T3-L1 preadipocytes induces the expression and secretion of 
IL-11. First, using a combined shRNA and dominant-negative mutant approach, we 
provide evidence that IL-11 acts in an autocrine fashion via the gp130 cytokine              
co-receptor signaling subunit to inhibit adipogenesis. Second, by taking advantage of a 
well-characterized panel of chimeric gp130 receptor mutants, we demonstrate that the 
activation of gp130-dependent signaling is sufficient to inhibit adipogenesis, and more 
specifically, that the gp130-mediated activation of the STAT1 transcription factor is 
necessary for this effect. Conversely, we find that the depletion of endogenous STAT1 
rescues adipogenesis from the anti-adipogenic effects of both IL-11 and PGF2α. 
Collectively, our findings support a model in which PGF2α inhibits adipocyte 
differentiation by establishing a calcineurin-dependent, IL-11-mediated autocrine 
negative feedback loop, that acts via gp130 to block adipogenesis through the essential 
actions of the STAT1 transcription factor. 
 In addition to IL-11, we find that Nurr1, an orphan nuclear hormone 
receptor, is also highly upregulated by the PGF2α/calcineurin-signaling pathway during 
the early stages of adipogenesis. Using a panel of CREB transcription factor mutants and 
a shRNA knockdown approach, we show that the CREB transcription factor and more 
specifically, its association with members of the CREB-regulated transcriptional co-
activator (CRTC) family of proteins is required for PGF2α to induce Nurr1 expression. 
xxi 
 
Furthermore, using a conditionally active CRTC2 mutant, we demonstrate that activation 
of CRTC proteins is sufficient to both induce Nurr1 expression and inhibit adipocyte 
differentiation. Finally, using a dominant-negative approach, we provide evidence that 
Nurr1 is involved in mediating the inhibitory effects of PGF2α on adipogenesis. Further, 
using Nurr1 mutants that are either deficient in their ability to bind DNA or 
heterodimerize with RxR, we demonstrate that Nurr1 requires its direct DNA binding 
activity, but not its interaction with RxR to inhibit adipogenesis. Taken together, these 
results demonstrate that, in addition to the IL-11 cytokine, the PGF2α/calcineurin-
signaling pathway also activates a CRTC/CREB/Nurr1-dependent signaling cascade to 
inhibit adipocyte differentiation. 
 In summary, my studies have helped to identify and delineate two independent 
signaling pathways that function downstream of calcineurin to mediate the inhibitory 
effects of PGF2α on adipogenesis: the IL-11/gp130/STAT1- and the 
CRTC/CREB/Nurr1-signaling pathways. Thus, the current findings of this dissertation 
project provide significant new insights into the molecular mechanisms by which the 
PGF2α/calcineurin-signaling pathway acts to inhibit adipocyte differentiation. 
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 CHAPTER I  
INTRODUCTION
1. Epidemiology and sequela of obesity: Obesity, an excessive accumulation of adipose 
tissue, is a major public health problem and is emerging as a worldwide epidemic in both 
developed and developing countries. The Centers for Disease Control and Prevention 
(CDC) report that about one-third of USA adults (34.9%) are already obese in 2012, 
while childhood obesity is increasing at an alarming rate with 18% children in USA aged 
between 6 and 11 years being classified as obese (Ogden, 2013). Further, the World 
Health Organization (WHO) reports that obesity has doubled worldwide since 1980 and 
about 500 million adults worldwide are currently obese (WHO, 2013). Obesity is a major 
risk factor for the development of several co-morbidities such as insulin resistance, type 2 
diabetes, coronary artery disease, hypertension, hyperlipidemia and several cancers (De 
Pergola and Silvestris, 2013; Kahn and Flier, 2000; Kahn et al., 2006; Nakamura et al., 
2013; Van Gaal et al., 2006). These obesity-associated diseases are linked to reduced life 
expectancy and premature death (Olshansky et al., 2005). Hence, it is important to 
understand the development of adipose tissue and obesity at the molecular level in order 
to identify better therapeutic targets to treat obesity and its associated complications. 
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2. Adipocytes and their physiological roles: Adipose tissue is primarily comprised of 
specialized, lipid-storing cells called adipocytes. These specialized cells are 
evolutionarily developed to store excess energy in the form of triglycerides during 
abundant availability of food and to release energy in response to starvation and flight or 
fight (Rosen and Spiegelman, 2006; Spiegelman and Flier, 2001). In addition to this 
important role in energy homeostasis, adipocytes also perform an important endocrine 
function and secrete a variety of biologically active molecules such as leptin, adiponectin, 
resistin, TNFα, IL-6, angiotensinogen, fatty acids and others (Fruhbeck et al., 2001; 
Kershaw and Flier, 2004; Vazquez-Vela et al., 2008; Waki and Tontonoz, 2007). 
Collectively, these molecules are called adipokines and are known to regulate a variety of 
functions including food intake, insulin responsiveness, cardiovascular function, vascular 
remodeling and the immune response (Trujillo and Scherer, 2006; Vazquez-Vela et al., 
2008; Waki and Tontonoz, 2007). Importantly, leptin secreted predominantly by 
adipocytes acts on the feeding center in the hypothalamus and inhibits appetite and food 
intake (Friedman and Halaas, 1998). In fact, the ob/ob mouse that is deficient in leptin 
and the db/db mouse that has a defective leptin receptor develop obesity at a very early 
age and are used as models to study obesity and type 2 diabetes (Chen et al., 1996; 
Coleman, 1978; Drel et al., 2006). In addition, adiponectin secreted by adipocytes 
increase the insulin sensitivity, whereas resistin, IL-6 and TNFα are shown to induce 
insulin resistance (Trujillo and Scherer, 2006). Thus, adipokines regulate whole body 
metabolism by regulating food intake and insulin sensitivity. Collectively, adipocytes 
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regulate energy homeostasis through storage and release of excess energy, and whole 
body metabolism by secreting a variety of adipokines. 
 
3. Development of obesity and associated complications: Adipocytes contribute to the 
development of adipose tissue mass by two mechanisms: 1) an increase in the size of 
adipocytes (hypertrophy) due to storage of energy as triglycerides, and 2) an increase in 
the number of adipocytes (hyperplasia) due to de novo generation of adipocytes known as 
adipogenesis (Hirsch and Batchelor, 1976; Spalding et al., 2008). Both adipocyte 
hyperplasia and hypertrophy play a crucial role in the development of obesity. Adipocyte 
hyperplasia plays a critical role in setting the number of adipocytes during early stages of 
childhood development and the number then stays constant into adulthood. This initial 
hyperplasia determines the degree of adipose tissue cellularity and subsequent propensity 
to develop obesity in adulthood (Brook et al., 1972; Hirsch and Batchelor, 1976; Knittle 
et al., 1979; Prins and O'Rahilly, 1997). In the adult, in the settings of positive energy 
balance, adipocyte hypertrophy through excessive accumulation of triglycerides 
contributes to the excessive accumulation of adipose tissue mass resulting in the 
formation of large, lipid-filled, dysfunctional, hypertrophic adipocytes (Hoffstedt et al., 
2010; Krotkiewski et al., 1983; Weyer et al., 2000). These large dysfunctional 
hypertrophic adipocytes eventually become unable to store any additional energy. As 
long as new, small insulin-sensitive adipocytes are generated from the precursor cells 
through adipogenesis, the excess energy can be stored by these new cells (Gray and 
Vidal-Puig, 2007; Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). However, 
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this essential adipogenic process is inhibited in extreme obesity by inflammatory 
mediators as discussed later in this chapter. In the absence of new adipocytes, the excess 
energy can be “spilled-over” and deposited as fat in non-adipose tissues such as liver, 
skeletal muscle, heart muscles, pancreatic islets and the perivascular tissues. Since these 
tissues are not specialized to store lipids, this can result in lipotoxicity in these tissues 
leading to tissue dysfunction such as insulin resistance and inability to secrete insulin 
(Gray and Vidal-Puig, 2007; Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). In 
fact, transplantation of intact functional adipose tissue into both a lipodystrophy mouse 
model (Gavrilova et al., 2000; Moitra et al., 1998) and a leptin deficient obese mouse 
model with severe metabolic abnormalities (Sennello et al., 2006) resulted in 
improvement in overall metabolic profile and insulin sensitivity. This shows that the lack 
of functional adipose tissue capable of storing excess energy contributes to the 
development of metabolic abnormalities in obesity. In addition, the large dysfunctional 
adipocytes begin to secrete a more pathological array of adipokines such as resistin, 
TNFα and IL-6 that are known to induce insulin resistance (Qatanani and Lazar, 2007). 
Collectively, impaired adipogenesis leading to lipotoxicity to non-adipose tissues and 
pathological array of adipokines secreted by dysfunctional adipocytes contribute to the 
development of obesity associated complications such as insulin resistance and type 2 
diabetes.  
 
4. Obesity, inflammation and impaired adipogenesis: Though the total number of 
adipocytes remains constant in adulthood, about 10% of the adipocytes are renewed 
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annually throughout life (Spalding et al., 2008). The newly generated small insulin-
sensitive adipocytes are essential as they store excess energy and prevent lipid spill-over 
to non-adipose tissues (Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). Thus, 
adipogenesis increases the overall lipid buffering capacity of adipose tissue and prevents 
lipotoxicity to non-adipose tissues. However, obesity is considered as an inflammatory 
condition and a variety of inflammatory cells such as macrophages, T lymphocytes, B 
lymphocytes, natural killer cells and neutrophils are recruited into adipose tissue (Cildir 
et al., 2013; Nishimura et al., 2009; Talukdar et al., 2012; Weisberg et al., 2003; Winer et 
al., 2011; Xu et al., 2003). These inflammatory cells produce a variety of inflammatory 
mediators such as IL-6 and TNFα, which create a low-grade chronic inflammatory 
condition in adipose tissue (Chawla et al., 2011; Gregor and Hotamisligil, 2011). In 
addition, the large dysfunctional adipocytes in obesity also secrete various inflammatory 
mediators (Qatanani and Lazar, 2007). These inflammatory mediators are known to 
potently inhibit the differentiation of preadipocytes into mature adipocytes (Gustafson 
and Smith, 2006; Xu et al., 1999). In fact, several line of evidence show that adipogenesis 
is impaired in obese patients. The number of preadipocytes that undergo differentiation is 
decreased in obese patients (Isakson et al., 2009) and these patients show a decreased 
number of committed preadipocytes (Tchoukalova et al., 2007). Further, the expression 
of genes involved in adipogenesis is decreased in type 2 diabetic patients (Dubois et al., 
2006). Collectively, this evidence shows that preadipocytes from obese individuals have 
impaired potential to differentiate into adipocytes. In the absence of new insulin-sensitive 
adipocytes, the lipid buffering capacity of adipose tissue is lost, resulting in lipid spill 
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over, lipotoxicity and subsequent development of type 2 diabetes (Tan and Vidal-Puig, 
2008; Virtue and Vidal-Puig, 2010). The direct link between obesity, inflammation and 
diabetes is evident from the finding that the obese mouse model that lacks the expression 
of TNFα shows enhanced insulin sensitivity and glucose homeostasis (Uysal et al., 
1997). Given the potential role of the inflammatory mediators in inhibiting adipogenesis, 
it is important to understand the molecular mechanisms by which they inhibit 
adipogenesis to identify better therapeutic targets to block this inhibitory effect on 
adipogenesis and consequently, to treat the obesity-associated complications such as type 
2 diabetes.  
 
5. Adipogenesis - An overview: Adipogenesis is a highly complex, multistep process 
that involves the initial commitment of multipotent stem cells into the adipogenic lineage 
and subsequent terminal differentiation into mature adipocytes. Cell culture systems are 
widely used to understand the adipocyte differentiation and they faithfully recapitulate 
the in vivo adipogenic process (Armani et al., 2010). 
 
5.1 Preadipocytes: Much of our current understanding about the molecular mechanisms 
of adipocyte differentiation comes from studies using preadipocyte cell culture systems 
(Rosen and MacDougald, 2006). Preadipocytes are cells committed to the adipocyte 
lineage and have lost their potential to differentiate into other cell types. Both primary 
preadipocytes and established preadipocyte cell lines are used to study adipocyte 
differentiation (Green and Meuth, 1974; Gregoire et al., 1990; Nougues et al., 1988). 
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Primary preadipocytes are derived from the vascular stromal fraction of adipose tissue. 
These primary preadipocytes can be induced to differentiate into mature adipocytes with 
a combination of adipogenic factors such as dexamethasone, insulin and 3-isobutyl-1-
methylxanthine (Armani et al., 2010). However, these primary cells cannot be cultured 
for prolonged periods and do not maintain the differentiation state for extended periods of 
time (Otto and Lane, 2005). In contrast, immortalized preadipocyte cell lines such as 
3T3-L1 and 3T3-F442A were developed from non-clonal Swiss 3T3-L1 cells by Green 
and associates in the 1970s and can be induced to differentiate into mature adipocytes 
(Green and Meuth, 1974; Green and Kehinde, 1975; Green and Kehinde, 1976). These 
two cell lines recapitulate much of the key features of adipogenesis in vivo such as 
morphological changes, expression of lipogenic enzymes, extensive lipid accumulation 
and sensitivity to key hormones that have effects on this cell type. In fact, subcutaneous 
implantation of 3T3-F442A cells into mice can form functional adipose tissue (Green and 
Kehinde, 1979). Therefore, the 3T3-L1 and 3T3-F422A cell lines provide a perfect model 
to study adipocyte differentiation in vitro. 
 
5.2 Process of adipocyte differentiation: The differentiation of preadipocytes into 
mature, lipid-filled adipocytes is a multistep process which includes initial growth arrest, 
mitotic clonal expansion and terminal differentiation into mature adipocytes (Gregoire et 
al., 1998). The differentiation process is regulated by a sequential expression of 
transcription factors including C/EBP family members and PPARγ. In this transcriptional 
cascade, C/EBPβ and C/EBPδ are expressed within few hours of induction of 
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adipogenesis, whereas C/EBPα and PPARγ are expressed later and then, they 
coordinately induce the expression of adipocyte specific genes (Figure 1) (Rosen and 
MacDougald, 2006).  
 
5.3 Initial growth arrest: In the preadipocyte cell culture system, growth arrest is a 
prerequisite for the differentiation of preadipocytes into mature adipocytes. The initial 
growth arrest is achieved in cultured cell lines after contact inhibition and the cells arrest 
at the G0/G1 cell cycle boundary (Patel and Lane, 2000). However, absolute cell-cell 
contact is not required as confluent 3T3-F442A cells shifted to methylcellulose-stabilized 
suspension culture still differentiate into adipocytes (Pairault and Green, 1979). Hence, 
growth arrest, but not cell-cell contact, is required for preadipocytes to differentiate into 
adipocytes. 
 
5.4 Induction of adipocyte differentiation with hormonal stimuli: Growth-arrested, 
post-confluent preadipocytes can be induced to terminally differentiate into mature, lipd-
filled, morphologically distinct adipocytes with a hormonal cocktail that consists of                  
3-isobutyl-1-Methylxanthine, Dexamethasone and pharmacological concentrations of 
Insulin or insulin-like growth factor 1 (IGF-1) in the presence of fetal bovine serum 
(Rosen and Spiegelman, 2000; Schmidt et al., 1990). This hormonal cocktail is referred 
as MDI. Mechanistically, 3-isobutyl-1-methylxanthine inhibits cAMP phosphodiestrase 
and transiently increases intracellular cAMP concentration, which results in the activation 
of protein kinase A (PKA) and subsequent activation of the downstream signaling  
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FIGURE 1. Schematic model showing the adipocyte differentiation and                    
the sequential expression of adipogenic transcription factors.  
 
 
Upon stimulation with the adipogenic cocktail MDI, two-day post confluent 3T3-L1 
preadipocytes differentiate into mature adipocytes in 6 to 8 days after stimulation. During 
the differentiation process, C/EBPβ and C/EBPδ are expressed within a few hours after 
the induction of adipogenesis. Once expressed, C/EBPβ and C/EBPδ bind to the C/EBPα 
and PPARγ promoters and induce their expression. Then, C/EBPα and PPARγ reinforce 
each other’s expression and induce adipocyte specific genes to confer the adipocyte 
phenotype. 
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pathways such as the cAMP response element-binding protein (CREB) transcription 
factor (Rosen and Spiegelman, 2000). CREB has been shown to regulate adipogenesis at 
multiple stages (Fox et al., 2008; Reusch et al., 2000; Zhang et al., 2004a) and is 
discussed later in this chapter. Dexamethasone is a glucocorticoid and is known to 
activate cytoplasmic, nuclear hormone, glucocorticoid receptors. It has been show to 
induce the expression of the early transcription factor, C/EBPδ (Cao et al., 1991). Insulin 
increases the percentage of cells that differentiate into mature adipocytes (Girard et al., 
1994). Although preadipocytes express few insulin receptors (Reed and Lane, 1980), the 
pharmacological concentration of insulin has been shown to cross-activate IGF-1 receptor 
signaling during adipogeneic induction (Smith et al., 1988). The activation of the insulin 
and IGF-1 receptors results in the activation of multiple signaling pathways that regulate 
adipogenic process. Thus, the hormonal cocktail MDI along with fetal bovine serum 
potently induces the preadipocytes to differentiate into mature adipocytes. 
 
5.5 Mitotic clonal expansion: When the post-confluent, growth-arrested preadipocytes 
in G0/G1 phase are stimulated with MDI, they synchronously re-enter the cell cycle and 
undergo two or three rounds of cell division, known as mitotic clonal expansion (MCE) 
(Cornelius et al., 1994; Tang et al., 2003b). The synchronous entry of growth-arrested 
preadipocytes into S phase is evidenced by changes in the cell cycle regulatory proteins 
such as expression and activation of cdk2-cyclin-E/A, down regulation of p27/kip1, 
hyperphosphorylation of Rb, translocation of cyclin D1 from the nuclei to cytoplasm and 
GSK-3β from cytoplasm to nuclei and incorporation of [3H] thymidine into DNA (Tang 
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et al., 2003b). The MCE is an important step for the differentiation of cultured 
preadipocytes into mature adipocytes. In fact, inhibiting cell cycle progression with 
rapamycin (Yeh et al., 1995a) or aphidicolin (Reichert and Eick, 1999) inhibits 
adiopocyte differentiation. Collectively, these findings indicate that mitotic clonal 
expansion plays a critical role in adipocyte differentiation. 
During the MCE process, DNA replication and epigenetic modifications in the 
chromatin structure at regulatory sequences increase the accessibility of critical cis-
elements to transactivating factors, which activate or de-repress the expression of genes 
required for terminal differentiation into mature adipocytes (Musri et al., 2010). For 
example, initial studies showed that the SWI/SNF chromatin remodeling enzyme 
complex promotes transcription of PPARγ gene by C/EBPβ (Salma et al., 2004). In the 
case of the C/EBPα promoter, HDAC1 blocks its expression, but once PPARγ protein 
accumulates, it is able to target HDAC1 to proteasome degradation and allows activation 
of C/EBPα expression (Zuo et al., 2006). A recent study using DNase I Hypersensitive 
site analysis to identify open chromatin regions during adipogenesis showed that major 
chromatin remodeling events occur within the first 4 h of adipogenesis and one third of 
PPARγ target hotspots are primed for subsequent PPARγ binding by 4 h of adipogenic 
stimulation (Siersbaek et al., 2011). Further, the histone hyperacetylation associated with 
gene expression is selectively increased at the promoter regions of adipogenic genes, 
whereas the expression of several histone deacetylases and the deacetylase enzyme 
activity associated with gene repression are decreased during adipocyte differentiation 
(Yoo et al., 2006). Collectively, chromatin remodeling that occurs during MCE leads to 
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adipocyte specific gene transcription and subsequent terminal differentiation into mature 
adipocytes. 
 
5.6 Terminal differentiation: After 2 or 3 rounds of MCE, cells withdraw from the cell 
cycle, enter into permanent growth-arrest and terminally differentiate into mature 
adipocytes over 6 to 8 days after adipogenic stimulation. During this stage, the cells 
express adipocyte specific genes like aP2, GLUT4, leptin, adiponectin and others. 
Subsequently, the preadipocytes acquire biochemical and morphological characteristics 
of mature adipocytes through de novo lipogenesis and accumulation of fat droplets, 
thereby acquiring a spherical, lipid filled morphology. In addition, the differentiated cells 
also acquire insulin sensitivity and respond to hormones that are known to act on 
adipocytes in vivo (Gregoire et al., 1998).  
 
6. Transcriptional regulation of adipogenesis: Adipocyte differentiation is regulated by 
a sequential and orchestrated expression of transcription factors. Several transcription 
factors involved in this process have been identified. However, C/EBPs and PPARγ are 
considered as critical transcription factors that determine the terminal differentiation of 
adipocytes (Farmer, 2006). In this transcriptional cascade, C/EBPβ and C/EBPδ are 
expressed within a few hours of induction of adipogenesis (Cao et al., 1991; Yeh et al., 
1995b). Once expressed, C/EBPβ and C/EBPδ coordinately bind to C/EBPα and PPARγ 
gene promoters and induce their expression. Once expressed, C/EBPα and PPARγ are 
able to bind to each other’s promoter and serve to reinforce each other’s expression via 
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positive feedback loop, thus ensuring their persistent expression in mature adipocytes 
(Rosen et al., 2002; Wu et al., 1996). More importantly, C/EBPα and PPARγ 
coordinately bind to the promoter of adipocyte specific genes and induce their expression 
to confer adipocyte phenotype (Tontonoz et al., 1994).  
 
6.1 Early transcription factors - C/EBPβ and C/EBPδ: C/EBPβ and C/EBPδ are 
basic-leucine zipper family of transcription factors that are rapidly expressed within 4 h 
of induction of adipocyte differentiation and are referred to as the early transcription 
factors of adipogenesis (Cao et al., 1991; Yeh et al., 1995b). The role of C/EBPβ, but not 
C/EBPδ, in adipogenesis has been extensively studied.  
Upon exposure to MDI, C/EBPβ expression is induced by methylisobutyxanthine 
which acts via CREB, whereas C/EBPδ expression is induced by dexamethasone (Cao et 
al., 1991; MacDougald et al., 1994; Zhang et al., 2004a). Further, CREB and its family 
members have been shown to bind to the proximal promoter of C/EBPβ and induce its 
expression within 4 h of adipogenic stimulation. Once expressed, C/EBPβ is 
phosphorylated by MAPK on Thr-188 between 2 to 4 h after induction and the 
phosphorylated C/EBPβ translocates into the nucleus (Tang et al., 2005), where this 
phosphorylation is sustained by cdk2 throughout the MCE phase (Li et al., 2007). Within 
the nucleus, C/EBPβ is further phosphorylated by GSK3β on Thr-179 or Ser-184 (Tang 
et al., 2005). These sequential phosphorylation events cause a conformational change that 
allows homodimerization and acquisition of DNA binding ability by C/EBPβ between 12 
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and 16 h after the induction of differentiation (Tang and Lane, 1999). In fact, C/EBPβ has 
been shown to bind to centromeric satellite DNA during this time period and the DNA 
binding activity coincides with the entry of cells into S phase of the cell cycle (Tang and 
Lane, 1999). After gaining DNA binding ability, C/EBPβ induces expression of cell 
cycle specific genes such as Cdc45I (cell division cycle 45 homolog), Mcm3 (mini-
chromosome maintenance complex component 3), Gins1 (GINS complex subunit 1), 
Cdc25c (cell division cycle 25 homolog c) and Mcm3 histone demathylase during MCE 
(Guo et al., 2012). C/EBPβ also induces the expression of epigenetic modifiers kdm4b, a 
histone demethylase (Guo et al., 2012), and G9a, a histone dimethylase during MCE (Li 
et al., 2013). Once induced, kdm4b acts as a co-activator of C/EBPβ to induce the 
expression of cell cycle specific genes, whereas G9a dimethylates the proximal promoters 
of PPARγ and C/EBPα, and inhibits their expression until the cells exit the cell cycle 
(Guo et al., 2012; Li et al., 2013). These findings clearly demonstrate that C/EBPβ plays 
a crucial role in the regulation of MCE and progression of the adipogenic process. 
The important role of C/EBPβ in adipocyte differentiation is evident from the 
finding that the mouse embryonic fibroblasts (MEFs) from C/EBPβ knockout mice fail to 
differentiate into adipocytes due to their inability to undergo MCE. In contrast, 
overexpression of C/EBPβ in these cells restores their capacity to differentiate into 
adipocytes (Tang et al., 2003a). The importance of C/EBPβ is further supported by the 
finding that a dominant-negative form of C/EBPβ, which prevents the nuclear 
translocation and DNA binding activity of endogenous C/EBPβ, inhibits differentiation 
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by blocking the MCE process (Zhang et al., 2004b).  Interestingly, ectopic expression of 
C/EBPβ in the 3T3-L1 cells induces them to undergo adipogenesis without exogenous 
adipogenic stimuli (Yeh et al., 1995b), and overexpression of C/EBPβ induces the 
multipotent NIH-3T3 cell line to differentiate into adipocytes (Wu et al., 1995), 
suggesting that C/EBPβ is sufficient to induce adipogenesis in certain settings. In the in 
vivo setting, C/EBPβ knockout mice show a slight reduction in adipose tissue mass 
compare to their wild type counter parts, whereas C/EBPδ knockout mice develop with 
normal amounts of adipose tissue. Conversely, in C/EBPβ and C/EBPδ double knockout 
mice, 85% of the animals die on day 1 after birth and the remaining mice survive, but 
show a dramatic reduction in adipose tissue mass and the expression of adipocyte specific 
genes (Tanaka et al., 1997). This shows that C/EBPβ and C/EBPδ transcription factors 
complement each other and play a critical role in the development of adipose tissue.  
In addition to the critical role of C/EBPβ and C/EBPδ proteins in the MCE, these 
proteins also regulate terminal differentiation by inducing C/EBPα and PPARγ 
expression. C/EBPα and PPARγ possess functional C/EBP binding sites in their 
promoters and are induced by C/EBP proteins (Christy et al., 1991; Clarke et al., 1997; 
Wu et al., 1996). Specifically, ectopic expression of C/EBPβ alone, or in combination 
with C/EBPδ in NIH 3T3-L1 cell line induces PPARγ expression and converts these cells 
into adipocytes (Wu et al., 1996).  
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6.2 Early transcription factor - cAMP responsive element binding protein (CREB): 
CREB is constitutively expressed in preadipocytes and is phosphorylated upon addition 
of adipogenic cocktail by signaling pathways initiated by methylisobutylxanthine and 
insulin through PKA and ERK signaling, respectively (Klemm et al., 1998; Martini et al., 
2009; Reusch et al., 2000). The important role of CREB in adipogenesis is evident from 
the findings that the activation of a constitutively active CREB is sufficient to induce 
adipogenesis in the absence of adipogenic cocktail, whereas either dominant-negative 
CREB or siRNA-mediated knockdown of CREB inhibits adipogenesis (Fox et al., 2006; 
Reusch et al., 2000). Indeed, CREB binds to the C/EBPβ promoter along with its family 
members and induces its expression (Fox et al., 2006; Niehof et al., 1997; Zhang et al., 
2004a). It also induces expression of cyclin D1 during the early stages of adipogenesis, 
which is required for the MCE process (Fox et al., 2008). Further, CREB directly binds to 
the PPARγ2 promoter and induces its expression (Fox et al., 2006). In addition, CREB 
also binds to the promoters of several other adipocyte-specific genes (Reusch et al., 
2000). Collectively, CREB plays an important role in adipogenesis by regulating the 
expression of multiple adipogenic genes. 
 
6.3 Proadipogenic transcription factor - C/EBPα: When preadipocytes are induced to 
differentiate with the adipogenic cocktail, C/EBPα is expressed after 2 days of induction 
(Cao et al., 1991; Yeh et al., 1995b). The early transcription factors C/EBPβ and C/EBPδ 
directly bind to the consensus binding sites in the proximal promoter of C/EBPα and 
induce its expression (Cao et al., 1991). Once expressed, C/EBPα binds to the promoter 
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of the adipocyte specific genes such as aP2, GLUT4 and SCD1, and transactivates their 
expression (Christy et al., 1989; Kaestner et al., 1990). Collectively, this results in 
terminal differentiation into mature adipocytes. In addition, C/EBPα is also an anti-
mitotic factor and stimulates the cells to exit MCE by inducing the expression of cell 
cycle inhibitor, p21 and by increasing its stability (Harris et al., 2001; Timchenko et al., 
1996). Further, C/EBPα inhibits cdk2 activity by directly interacting with p21 and cdk2, 
thereby preventing cell cycle progression (Harris et al., 2001). Thus, C/EBPα regulates 
adipogenesis by inhibiting MCE and inducing the expression of adipocyte specific genes. 
The important role of C/EBPα in adipocyte differentiation is evident from the loss 
and gain of function experiments in preadipocyte cell lines. The expression of antisense 
C/EBPα RNA in 3T3-L1 cells inhibits adipogenesis and prevents the expression of 
several adipocyte specific genes (Lin and Lane, 1992), whereas expression of C/EBPα in 
preadipocytes and mouse fibroblasts induces these cells to differentiate into adipocytes 
without the addition of adipogenic stimuli (Freytag et al., 1994; Lin and Lane, 1994). 
These results suggest that C/EBPα is both necessary and sufficient to induce 
adipogenesis. The crucial in vivo role of C/EBPα in adipose tissue development is 
evident from the analysis of C/EBPα knockout mice, as these mice die within a few 
hours after birth due to impairment of hepatic gluconeogenesis (Wang et al., 1995). 
Interestingly, these mice survived with selective expression of C/EBPα in liver, but failed 
to develop white adipose tissue, except in the mammary fat pat (Linhart et al., 2001). 
Further, replacement of C/EBPα with C/EBPβ in a mouse model results in decreased 
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development of white adipose tissue compared to its wild type litter mates (Chen et al., 
2000). Collectively, these findings show that C/EBPα plays a critical role in the 
adipocyte differentiation and the development of adipose tissue in vivo. 
In addition to its role in adipocyte differentiation and the expression of adipocyte 
specific genes, C/EBPα plays a crucial role in the insulin sensitivity of adipocytes. In 
fact, fibroblasts from C/EBPα null mice express low levels of PPARγ and fail to 
differentiate into mature adipocytes. While these cells differentiate into adipocytes with 
ectopic expression of PPARγ, these adipocytes show a complete absence of insulin-
stimulated glucose transport due to decreased expression and tyrosine phosphorylation of 
the insulin receptor and it downstream signaling protein, IRS-1 (Wu et al., 1999). This 
shows that C/EBPα specifically induces genes involved in the insulin sensitivity of 
mature adipocytes. 
 
6.4 Proadipogenic transcription factor - PPARγ: PPARγ belongs to the nuclear-
receptor superfamily of ligand-activated transcription factors (Feige et al., 2006) and is 
expressed as two isoforms, PPARγ1 and PPARγ2 from the same gene through alternative 
splicing and promoter usage (Zhu et al., 1995). Though PPARγ1 and PPARγ2 are 
expressed in adipocytes, PPARγ1 is expressed ubiquitously, whereas PPARγ2 expression 
is exclusively restricted in adipocytes (Vidal-Puig et al., 1996). PPARγ induces gene 
expression by binding to the promoter of its target genes at consensus nuclear hormone 
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binding sites as a heterodimer with its nuclear binding partner, retinoid X receptor (RXR) 
(Palmer et al., 1995).  
 
6.4.1 Regulation of the PPARγ transcriptional activity: PPARγ  is a ligand-activated 
transcription factor and while several lipid metabolites including polyunsaturated fatty 
acids, prostanoids, prostaglandin 15 deoxy -∆12, 14- prostgandin J2 are considered as 
putative ligands for PPARγ, an endogenous ligand that potently activates PPARγ has not 
yet been identified (Tontonoz and Spiegelman, 2008). Interestingly, PPARγ is the target 
for antidiabetic thiazolidinedione drugs (Lehmann et al., 1995) and these drugs are shown 
to increase adipocyte differentiation in vitro (Kletzien et al., 1992; Sandouk et al., 1993) 
and increase adipose tissue mass in vivo (Hallakou et al., 1997). 
In addition to its ligands, PPARγ activity is also regulated by several co-activators 
and co-repressors. In the absence of a ligand, PPARγ binds to NCoR (nuclear receptor 
co-repressor) and SMRT (silencing mediator for retinoid and thyroid receptor) 
transcriptional co-repressors (Guan et al., 2005), resulting in the inhibition of its 
transcriptional activity, whereas blocking the expression of both NCoR and SMRT by 
siRNA in 3T3-L1 cells results in their more efficient differentiation into adipocytes (Yu 
et al., 2005). Another co-repressor called receptor interacting protein 140 (RIP 140) has 
also been shown to inhibit PPARγ transcriptional activity (Debevec et al., 2007). Upon 
binding to a ligand, the co-repressor complex associated with PPARγ is replaced by co-
activators, resulting in the gene transcription (Perissi and Rosenfeld, 2005). Several 
transcriptional co-activators including CBP/p300, steroid receptor coactivators and 
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TRAP200/DRIP205 are known to directly interact with PPARγ and induce its 
transcriptional activity (Powell et al., 2007). In addition, several post translational 
modifications are known to regulate the transcriptional activity of PPARγ. The 
phosphorylation of PPARγ at S112 induced by ERK activation inhibits the transcriptional 
activity of PPARγ and blocks adipogenesis (Camp and Tafuri, 1997; Hu et al., 1996). 
Further, sumoylation of PPARγ at K107 inhibits its transcriptional activity (Ohshima et 
al., 2004; Yamashita et al., 2004). In addition, PPARγ is poly ubiquitinated and degraded 
by the proteasome (Floyd and Stephens, 2002; Hauser et al., 2000). Thus, it is clear that 
the PPARγ activity is regulated by multiple mechanisms, including multiple co-
activators, co-repressors and post translational modifications.  
 
6.4.2 Role of PPARγ in adipogenesis: During the adipogenic process PPARγ is 
expressed after 2 days of induction and its expression is induced by the early transcription 
factors C/EBPβ and C/EBPδ (Christy et al., 1991; Clarke et al., 1997; Wu et al., 1995). 
The delayed expression of PPARγ is important due to its anti-mitotic activity, which 
induces the cells to exit the cell cycle and undergo permanent growth-arrest (Altiok et al., 
1997). Once expressed, the more important function of PPARγ is to induce the expression 
of genes involved in lipogenesis and insulin sensitivity to confer the adipocyte phenotype 
(Rosen et al., 2000). Most adipocyte specific genes contain PPARγ binding sites and are 
shown to be regulated by PPARγ. A recent study with genome-wide ChIP-seq profiling 
of PPARγ:RxR-binding sites in differentiating 3T3-L1 cells demonstrated that the 
PPARγ:RxR heterodimer binds to more than 5000 gene promoters, with the majority of 
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the genes involved in glucose and lipid metabolism (Nielsen et al., 2008). In addition, 
PPARγ also induces the expression of C/EBPα. Thus, a positive feed-back loop exists 
between PPARγ and C/EBPα to reinforce each other expression and to maintain their 
expression in the mature adipocytes (Otto and Lane, 2005; Rosen et al., 2002).  
Multiple evidence show that PPARγ is the master regulator of adipogenesis and 
the failure of expression of PPARγ prevents adipogenesis. In fact, the ectopic expression 
of PPARγ induces fibroblasts to express adipocyte specific genes without adipogenic 
stimuli and subsequently, these cells accumulate triglycerides (Tontonoz et al., 1994). In 
contrast, embryonic stem cells that lack PPARγ fail to differentiate into adipocytes 
(Rosen et al., 1999). Interestingly, PPARγ can induce adipogenesis in C/EBPα deficient 
MEF, whereas C/EBPα cannot induce adipogenesis in the absence of PPARγ (Rosen et 
al., 2002). This shows that PPARγ alone is sufficient to induce adipogenesis. Though 
germline PPARγ deficiency is embryonic lethal (Barak et al., 1999), selective depletion 
of PPARγ2 in a mouse model resulted in decreased white adipose tissue mass and 
decreased insulin sensitivity (Rosen et al., 1999). Collectively, both in vitro and in vivo 
studies show that PPARγ is both sufficient and necessary for adipogenesis and is the 
master regulator of adipocyte differentiation. 
 
7. Extracellular factors regulating adipocyte differentiation: The efficiency of 
adipocyte differentiation both in vitro and in vivo is strongly influenced by the 
environmental milieu, with a fine balance of extracellular factors that positively and 
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negatively regulate the adipogenic process (MacDougald and Mandrup, 2002). The 
extracellular factors regulate adipogenesis through activation of multiple signaling 
pathways that ultimately induce or inhibit the expression of the above mentioned key 
adipogenic transcription factors. Various factors including several hormones, cytokines, 
growth factors and some pharmacological compounds are known to positively regulate 
adipogenesis (MacDougald and Mandrup, 2002). For example, insulin and IGF-1 are 
potent inducers of adipogenesis and are required for complete differentiation of 
preadipocytes into mature adipocytes (Girard et al., 1994; Smith et al., 1988). In contrast, 
several factors including Wnt, epidermal growth factor, resistin, PREF-1 and pro-
inflammatory cytokines TNFα, IL-6 and IL-11 are known to inhibit adipogenesis by 
blocking the expression of key adipogenic transcription factors (MacDougald and 
Mandrup, 2002). For example, Wnts, a family of secreted proteins, are considered as 
potent inhibitors of adipocyte differentiation. Interestingly, inhibition of Wnt signaling 
using a dominant-negative form of its downstream signaling protein TCF4 in 3T3-L1 
cells induces these cells to spontaneously differentiate into adipocytes in the absence of 
adipogenic stimuli (Bennett et al., 2002; Ross et al., 2000). Another important class of 
agents that are known to influence adipocyte differentiation both positively and 
negatively is the prostaglandins which are discussed below. 
 
7.1 Prostaglandins: Prostaglandins (PGs) are a group of lipid mediators and are 
synthesized through a series of enzymatic process from membrane phospholipids. First, 
arachidonic acid is liberated from membrane phospholipids by phospholipase A2. Then, 
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it is converted to PGH2, a common precursor of all PGs, by cyclooxygenase enzymes. 
Finally, PGH2 is metabolized to various PGs such as PGD2, PGE2, PGF2α, PGI2 and 
thromboxane A2 by the action of specific PG synthases (Breyer et al., 2001; Ricciotti and 
FitzGerald, 2011). After biosynthesis, prostaglandins are rapidly transported out of the 
cell and act in an autocrine and paracrine manner on their cognate PG receptors that 
belong to the membrane spanning G-protein couple receptors (Breyer et al., 2001; 
Ricciotti and FitzGerald, 2011). Though PGs are known to play an important role in 
mediating inflammation, they also regulate several cellular processes including adipocyte 
differentiation. Specific PGs have been shown to either promote or inhibit adipocyte 
differentiation. PGI and PGD2 metabolite PGJ2 have been shown to have a positive 
effect on adipocyte differentiation (Forman et al., 1995; Reginato et al., 1998). PGI 
promotes adipogenesis by inducing the expression of early transcription factors C/EBPβ 
and C/EBPδ through a cAMP-dependent mechanism (Aubert et al., 2000), while PGD2 
metabolite 15-deoxy-∆12, 14-prostaglandine J2 has been shown to potently induce 
adipocyte differentiation, possibly through its role as a putative endogenous ligand of 
PPARγ (Forman et al., 1995). In contrast, PGE2 and PGF2α are known as inhibitors of 
adipocyte differentiation (Inazumi et al., 2011; Serrero et al., 1992; Tsuboi et al., 2004). 
PGE2 and a selective agonist of EP receptor inhibit adipocyte differentiation by blocking 
the expression of PPARγ, whereas an EP receptor antagonist promotes adipocyte 
differentiation (Tsuboi et al., 2004). More importantly, PGF2α is a potent physiological 
inhibitor adipogenesis (Volat et al., 2012) and is discussed below.  
 
24 
 
 
7.2 PGF2α - A potent inhibitor of adipogenesis: 
7.2.1 PGF2α synthesis, signaling and functions: PGF2α is synthesized, as described 
earlier, from arachidonic acid by a series of enzymatic reactions. The terminal enzymes 
that catalyze the conversion of PGH2 to PGF2α are aldo-keto reductases (Akrs). Though 
several tissue specific isoforms of Akrs are expressed, Akr1b7 and Akr1b3 are highly 
expressed in preadipocytes and act as PGF2α synthases in these cells (Fujimori et al., 
2010b; Tirard et al., 2007). When Akr1b7 expression was depleted in a mouse model, 
these mice showed a significantly decreased level of PGF2α in their adipose tissue, 
which shows that Akr1b7 plays a critical role in the PGF2α synthesis in vivo (Volat et al., 
2012). Once synthesized and released, PGF2α binds and activates a specific Gαq coupled 
GPCR called the FP prostanoid receptor (Breyer et al., 2001; Narumiya et al., 1999). 
Activation of the FP receptor results in the stimulation of phospholipase C, an increase in 
intracellular calcium and the subsequent activation of several downstream signaling 
pathways including phosphotidylinositol-3 kinase, protein kinase C, mitogen-activated 
protein kinases, tyrosine kinases and stimulation of the Rho small G-protein and the 
activation of the β-catenin/TCF-signaling pathway (Breyer et al., 2001; Fujino and 
Regan, 2001; Pierce et al., 1999; Watanabe et al., 1994; Watanabe et al., 1995). The 
PGF2α-mediated signaling pathways have been shown to regulate various biological 
processes including bone remodeling, reproduction, inflammation, and vascular and 
endometrial remodeling (Agas et al., 2013; Ricciotti and FitzGerald, 2011). Importantly, 
PGF2α has been shown to potently inhibit adipocyte differentiation both in vitro and in 
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vivo (Casimir et al., 1996; Lepak and Serrero, 1993; Serrero et al., 1992; Volat et al., 
2012). 
 
7.2.2 Anti-adipogenic effect of PGF2α in cultured preadipocytes: Initial studies 
showed that arachidonic acid, the precursor of prostaglandins, inhibits adipocyte 
differentiation and the pretreatment with cyclooxygenase inhibitors block this inhibitory 
effect (Casimir et al., 1996). This showed that the prostaglandins synthesized from 
arachidonic acid inhibit adipogenesis. Further, prostaglandins F2α, E2 and D2 were able 
to mimic the inhibitory effect of arachidonic acid when added to the adipogenic cocktail. 
Among these prostaglandins, PGF2α is the most effective and highly potent in inhibiting 
adipocyte differentiation (Casimir et al., 1996). More importantly, PGF2α is produced by 
preadipocytes themselves and its production is highest in dividing nonconfluent cells. But 
its level dropped by approximately 70% after stimulation and the level remained at low 
throughout the differentiation process (Miller et al., 1996). This shows that PGF2α seems 
to act as a negative regulator of adipocyte differentiation. Further, the activation of the 
cognate PGF2α receptor (FP receptor) with a selective agonist, fluprostenol inhibits 
preadipocytes differentiation, whereas FP receptor antagonists prevents the inhibitory 
effects of fluprostenol on adipogenesis (Casimir et al., 1996; Miller et al., 1996). This 
confirms that the activation of FP receptor inhibits adipogenesis. FP receptors are present 
throughout differentiation, as the membranes prepared from either 3T3-L1 preadipocytes 
or adipocytes exhibits specific binding for PGF2α (Miller et al., 1996). Given the fact 
that endogenous PGF2α production decreases during the differentiation and the FP 
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receptors present throughout the differentiation process, the FP-receptor mediated 
inhibition of adipogenesis appears to be regulated by the alteration in the PGF2α 
concentration rather than the receptor expression (Miller et al., 1996). In addition, when 
several prostaglandins were examined, structurally similar prostaglandin 9 alpha, 11 beta-
PGF2α potently inhibited adipogenesis, suggesting that the structural characteristics of 
PGF2α is required for its inhibitory effect on adipogenesis (Lepak and Serrero, 1993).  
 
7.2.3 Mechanisms of PGF2α-mediated inhibition of adipocyte differentiation: 
Several mechanisms have been proposed for the inhibitory effects of PGF2α on 
adipogenesis. Initial studies showed that the activation of FP receptor with fluprostenol 
transiently increases the intracellular calcium and a calcium/calmodulin-dependent 
protein kinase inhibitor rescues the inhibitory effect (Miller et al., 1996). This study 
suggested that the PGF2α-induced increase in intracellular calcium inhibits adipogenesis 
by activation of the calcium-dependent downstream signaling pathways. Similarly, a 
number of studies have shown that increases in intracellular calcium concentration during 
the early phase of human and 3T3-L1 preadipocyte differentiation act to potently inhibit 
adipogenesis (Neal and Clipstone, 2002; Ntambi and Takova, 1996; Shi et al., 2000). 
Further, PGF2α-mediated activation of ERK has been linked to the inhibition of 
adipogenesis by causing an inhibitory phosphorylation of PPARγ (Reginato et al., 1998). 
In addition, PGF2α has been shown to inhibit adipogenesis through upregulation of HIF-
1 transcription factor under normoxic condition (Liu and Clipstone, 2008). HIF-1 induces  
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FIGURE 2. Schematic model showing the PGF2α-mediated inhibition of adipocyte 
differentiation via activation of the calcineurin phosphatase.  
 
PGF2α activates Gαq coupled G-protein coupled receptor and increases the intracellular 
concentration of Ca2+. The increased intracellular Ca2+ activates calcium-dependent 
phosphatase, calcineurin. The PGF2α/calcineurin-signaling pathway inhibits adipocyte 
differentiation by blocking the expression of late transcription factors (C/EBPα and 
PPARγ), but the early transcription factors (C/EBPβ and C/EBPδ) are not affected. 
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the expression of a HDAC associated transcriptional repressor DEC1, which has been 
shown to directly repress the PPARγ promoter. Interestingly, trichostatin A, an HDAC 
inhibitor rescues differentiation from PGF2α, suggesting the role of a HDAC regulated 
gene, possibly DEC1 in mediating the inhibitory effects of PGF2α on adipogenesis (Liu 
and Clipstone, 2008). More importantly, studies from our laboratory have shown that 
PGF2α inhibits adipogenesis through a calcium-dependent phosphatase calcineurin (Liu 
and Clipstone, 2007), which is discussed below. 
 
7.2.4 PGF2α inhibits adipogenesis through calcineurin-dependent signaling: Initial 
studies from our laboratory showed that calcineurin activity is required for the inhibitory 
effects of calcium ionophore, as the presence of the calcineurin inhibitors either CsA or 
FK506, rescued differentiation from the inhibitory effect of calcium inophore on 
adipogenesis (Neal and Clipstone, 2002). In addition, ectopic expression of a calcium-
independent, constitutively active calcineurin inhibited differentiation of 3T3-L1 cells 
into adipocytes (Neal and Clipstone, 2002). Collectively, these findings show that 
calcineurin activity inhibits adipocyte differentiation. Later, studies from our laboratory 
showed that the calcineurin phosphatase acts as a potent downstream effector in 
mediating the inhibitory effects of PGF2α (Liu and Clipstone, 2007). In fact, PGF2α 
requires Gαq, but not Gβγ subunits of G-protein to inhibit adipocyte differentiation (Liu 
and Clipstone, 2007). The activation of Gαq is well known to activate phospholipase C, 
which results in a subsequent increase in intracellular calcium (Katritch et al., 2013). 
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When the 3T3-L1 cells are induced to differentiate in the presence of PGF2α along with 
an inhibitor of receptor-mediated plasma membrane Ca2+-influx or a membrane 
permeable Ca2+-chelator, both inhibitors rescue adipocyte differentiation, suggesting that 
PGF2α-induced increase in intracellular calcium is responsible for the inhibition of 
adipogenesis (Liu and Clipstone, 2007). It is also well known that the activity of 
calcineurin phosphatase is regulated by intracellular calcium and calcineurin acts as a 
negative regulator of adipocyte differentiation (Neal and Clipstone, 2002). Interestingly, 
pretreatment with either a calcineurin inhibitor, cyclsporin A or FK506 or expression of a 
calcineurin inhibitory VIVIT peptide completely rescues adipocyte differentiation from 
the PGF2α-mediated inhibitory effect, suggesting that PGF2α acts through calcineurin 
phosphatase to inhibit adipogenesis. Interestingly, PGF2α does not prevent the mitotic 
clonal expansion during adipogenesis as well as expression of early transcription factors 
C/EBPβ and C/EBPδ, whereas the expression of key adipogenic factors C/EBPα and 
PPARγ is inhibited by PGF2α (Figure 2) (Liu and Clipstone, 2007). However, the precise 
molecular mechanism by which the PGF2α/calcineurin-signaling pathway inhibits 
adipogenesis by blocking the C/EBPα and PPARγ expression is not known. 
 
7.2.5 Role of PGF2α in physiological inhibition of adipose tissue development          
in vivo: A recent study using Akr1b7 knockout mice shows that PGF2α plays a critical 
negative regulatory role in the development of adipose tissue in vivo (Volat et al., 2012). 
As mentioned earlier, Akr1b7 is a terminal enzyme involved in the biosynthesis of 
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PGF2α from its precursor PGH2 and is highly expressed in adipocyte precursor cells. 
Further, its expression is down regulated during adipocyte differentiation, whereas 
overexpression of Akr1b7 inhibits differentiation process of 3T3-L1 preadipocytes. 
Interestingly, Akr1b7 knockout mice showed a significantly decreased level of PGF2α in 
adipose tissue compared to wild type littermates and an increase in basal white adipose 
tissue mass under normal feeding condition. Under a high fat diet, these animals rapidly 
gained weight with a five-fold increase in plasma leptin level compared to their wild type 
counterparts and developed insulin resistance. In contrast, daily administration of a 
synthetic PGF2α, cloprostenol for 3 months to Akr1b7-/- mice resulted in a significant 
decrease in plasma leptin level, which indicates a reduced white adipose tissue mass. 
Further, BrdU treatment to asses adipose tissue expansion in high fat diet fed Akr1b7-/- 
mice showed a 3.5 fold increase in BrdU-positive adipocyte-associated nuclei in gonadal 
WAT from Akr1b7-/- compared with wild type, whereas cloprostanol treatment reduced 
the production of new adipocytes under this condition to the level of WT mice fed with 
HF-diet (Volat et al., 2012). This suggests that PGF2α inhibits adipocyte differentiation 
and the generation of new adipocytes. Collectively, it is evident that PGF2α acts as a 
physiological inhibitor of adipose tissue development in vivo. Hence, it will be interesting 
to decipher the underlying molecular mechanisms involved in mediating the inhibitory 
effects of PGF2α on adipocyte differentiation. 
 
8. Summary: Adipocyte differentiation is a highly complex, well regulated cellular 
process that is influenced by several positive and negative exogenous factors. One such 
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factor that is known to potently inhibit adipogenesis both in vitro and in vivo is PGF2α. 
Previous studies from our laboratory have shown that PGF2α acts through calcium-
dependent phosphatase, calcineurin to inhibit adipocyte differentiation. However, the 
precise molecular mechanism by which the PGF2α/calcineurin-signaling pathway 
inhibits adipogenesis is not known. In this dissertation project, we have explored the 
underlying molecular mechanisms involved in mediating the inhibitory effects of PGF2α 
on adipogenesis and found that IL-11, an IL-6 cytokine family member and Nurr1, an 
orphan nuclear receptor are strongly induced by the PGF2α/calcineurin-signaling 
pathway and play a role in mediating its inhibitory effects on adipocyte differentiation. 
We have further explored the underlying mechanisms by which IL-11 and Nurr1 act to 
inhibit adipogenesis and have delineated the pathways and mechanisms involved. 
Collectively, our studies have afforded significant new insights into the mechanism by 
which the physiologically relevant anti-adipogenic factor PGF2α acts to inhibit the 
adipogenic process. 
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CHAPTER II 
MATERIALS AND METHODS
1. Cell culture and adipocyte differentiation: The 3T3-L1 preadipocyte cells were 
plated at the concentration of 8x104 cells per well of a 6-well plate and were grown to 
confluence in DMEM/high glucose media (HyClone) supplemented with 10% fetal 
bovine serum (Atlanta Biologicals). After 2 days, the confluent cells were treated for 48 h 
with growth media plus the adipogenic cocktail, MDI (0.5 mM Methylisobutylxanthine, 
1 µM Dexamethasone, and 10 µg/ml Insulin; all from Sigma). Cells were re-fed with 
growth media containing 10 µg/ml insulin at day 2 and every 2 days thereafter with 
growth media alone. Where indicated, cells were also treated for the first 48 h of the 
induction period with the indicated concentrations of PGF2α (Calbiochem), 1 µg/ml 
cyclosporin A (Calbiochem), recombinant murine IL-11 (50 ng/ml; Peprotech) and 
recombinant mouse erythropoietin (40 ng/ml; BD Pharmingen). In some experiments, 
conditioned media collected from 3T3-L1 cells ectopically expressing cDNAs encoding 
either murine IL-11 or murine erythropoietin were used instead of recombinant cytokines 
with identical results. To assess the extent of adipocyte differentiation, cells were fixed 
on day 8 post-stimulation with 10% formalin for 60 min at 4°C, then after two washes 
with phosphate buffered saline (PBS), were stained with filtered Oil Red O solution 
(Sigma) for 2 hrs at room temperature. After staining, the cells were washed with PBS to 
remove unbound dye and the plates were scanned. Cells were then counter stained with 
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hematoxylin (Sigma) for 4 min and, after washing with PBS, were visualized by light 
microscopy and photographed (40X).  
 
2. Plasmid constructs:  
2.1 Dominant-negative gp130: The dominant-negative version of gp130 (DN-gp130) 
was generated by using a murine gp130 cDNA (Open Biosystems; clone I.D. 6834623) 
as a template in a polymerase chain reaction (PCR) using PfuTurbo (Stratagene) together 
with gene-specific primers designed to delete the C-terminal 213 amino acids containing 
conserved amino acid residues known to be essential for gp130-mediated signaling 
events (Taga and Kishimoto, 1997) and replacing them with a FLAG epitope tag 
followed by a stop codon. The resulting DN-gp130 construct was then subsequently 
introduced into the MSCV-GFP retroviral expression vector.  
 
2.2 EpoR/gp130-WT, 1F and 4F: The wild-type EpoR/gp130 chimera and 
corresponding mutant chimeras containing tyrosine-to-phenylalanine substitutions in 
conserved residues of the gp130 cytoplasmic domain were kind gifts of Dr. Fred Schaper, 
RWTH Aachen, Germany (Schaper et al., 1998; Schmitz et al., 2000). The wild type 
EpoR/gp130 chimera was PCR-amplified using gene-specific primers and the resulting 
PCR product was digested with SalI and MfeI, and introduced into the XhoI/EcoRI site 
of the MSCV-GFP retroviral vector, giving rise to MSCV-EG-WT. To generate MSCV-
EG-1F and MSCV-EG-4F, Nsi I/Bam HI fragments corresponding to the C-terminal 
region of murine gp130 containing either a Y759F single substitution (1F), or 
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Y767F/Y814F/Y905F/Y915F quadruple substitutions (4F) were introduced into Nsi 
I/Bam HI-digested MSCV-EG-WT backbone. The EpoR/gp130-4F “add back” mutants 
were generated using PCR cloning techniques to fuse peptide sequences previously 
reported to selectively activate either STAT1 (PTPSFGYDKPHV), or STAT3 
(PTPSFGYFKQHV) (Gerhartz et al., 1996), in-frame with the extreme C-terminus of 
EG-4F. Briefly, EG-4F was used as a template in a PCR reaction with the forward primer 
5’-CTTCA TGCAT GTCAT CTTCT AGGC-3’ together with either 5’-AGGAT CCTAC 
ACGTG TGGCT TGTCG TATCC GAAGG ATGTT GGCGT CTGTG GTAAG 
AAACT TTTAG GC-3’ or 5’-GAGGA TCCTA CACGT GCTGC TTGAA GTATC 
CGAAG GATGT TGGCG TCTGT GGTAA GAAAC TTTTA GGC-3’ as reverse 
primers. The resulting PCR products were digested with Nsi I/Bam HI and introduced 
into the corresponding sites of MSCV-EG-4F giving rise to EG-4F-STAT1 and EG-4F-
STAT3, respectively.  
 
2.3 STAT1, IL-11 and CRTC2 specific shRNAs: To generate retroviral constructs 
capable of expressing shRNAs specific for STAT1, plasmids encoding STAT1-specific 
shRNAs in the lentiviral vector pLKO.1 were purchased from Open Biosystems (Clone 
I.D. TRCN0000054924 and TRCN0000054927) and used as templates in a PCR reaction 
together with the forward primer 5’-CTCTC AATTG TATCG ATCAC GAGAC 
TAGCC TC-3’; and the reverse primer 5’-CCTCA AGCTT GGATG AATAC TGCCA 
TTTGT CTCG-3’. The resulting PCR fragments were digested with Mfe I and Hind III 
and cloned into the pSR-GFP/Neo vector (OligoEngine) previously digested with Eco RI 
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and Hind III to generate pSR-STAT1-924 and pSR-STAT1-927, respectively. The 
shRNA retroviral constructs specific for murine IL-11 and murine CRTC2 were 
generated by the identical approach using plasmids encoding IL-11 (Open Biosystems; 
Clone I.D. TRCN0000066459) and CRTC2 (Open Biosystems; Clone I.D. 
TRCN00000176098)-specific shRNAs in the lentiviral vector pLKO.1. The control 
shRNA retroviral vector specific for firefly luciferase has been described previously (Liu 
and Clipstone, 2008).  
 
2.4 MSCV-DsRed2-PPARγ2: The MSCV-DsRed2-PPARγ2 construct was generated by 
isolating a blunted Afl III/Xba I fragment of the full-length murine PPARγ2 cDNA from 
pSVSport-PPARγ2 (Addgene) and introducing it into MSCV-DsRed2 at the blunted 
EcoRI site.  
 
2.5 Nurr1-WT, Nurr1-AA and Nurr1-KLL: Plasmids encoding the murine wild type 
Nurr1 (Nurr1-WT), the DNA binding defective Nurr1-C280A/E281A (Nurr1-AA), and 
the RxR binding-defective Nurr1-K554A/L555A/L556A (Nurr1-KLL) in the pCMX 
expression vector were kindly provided by Dr. Thomas Perlmann (Ludwig Institute for 
Cancer Research, Karolinska Institute, Stockholm, Sweden). To generate a FLAG-tagged 
version of WT-Nurr1, the pCMX-wtNurr1 plasmid was used in a polymerase chain 
reaction using PfuTurbo (Stratagene) and 5’- CTCAGA TCTGAG ACCATG GACTAC 
AAGGAC GACGAT GACAAG ATGCCT TGTGTT CAGGCG CAGTAT GG - 3’ as a 
forward primer together with 5’- CTCGAT CATATG CGTAGT GGCCAC GTAGTT 
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CTG - 3’ as a reverse primer. The resulting PCR product encoding the FLAG peptide 
fused in-frame with the 5’ end of the wtNurr1 sequence was digested with Bgl II and Nde 
I, then ligated into the Bgl II/Xho I-digested pMSCV-GFP retroviral expression vector 
together with an Nde I/Xho I fragment encompassing the 3’ end of the wtNurr1 cDNA 
isolated from pCMX-wtNurr1. FLAG-tagged versions of Nurr1-KLL and Nurr1-AA 
were constructed in a similar manner using Nde I/Xho I fragments isolated from pCMX-
Nurr1-KLL and pCMX-Nurr1-AA, respectively. 
 
2.6 Dominant-negative Nurr1: The dominant-negative Nurr1 (DN-Nurr1) construct is 
comprised of Nurr1 amino acids  from 94 to 365, lacking both N- and C-terminal 
transactivation domains, fused in-frame with the N-terminal 100 amino acids of the ZPF-
10 KRAB family member containing the KRAB transcriptional repressor domain. First, 
an Ndelta94-Nurr1 construct lacking the N-terminal 94 amino acids of Nurr1 was 
generated by using the pCMX-wtNurr1 plasmid in a PCR reaction with 5’- TCTGAG 
ACCATG TTCTAC CCATAC GACGTC CCAGAC TACGCT GTAGAA GACATT 
CAGATG CAC - 3’ as the forward primer and 5’ -CTCGAT CATATG CGTAGT 
GGCCAC GTAGTT CTG - 3’ as a reverse primer. The resulting PCR product was 
digested with Bgl II and Nde I and ligated together with an Nde I/Xho I fragment 
encompassing the 3’ end of the wtNurr1 cDNA isolated from pCMX-wtNurr1 into Bgl 
II/Xho I-digested MSCV-GFP to give the MSCV-Ndelta94Nurr1 construct. Second, the 
ZPF-10 plasmid (Open Biosystems) was used in a polymerase chain reaction together 
with 5’- ACAGGA TCCCTC TCCCCC CTCACC TCCGGT GAGTCT GATCAT 
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GGATGC TAAGTC ACTAAC TGCCTG GTC - 3’ as a forward and 5’ - GAGCTC 
GAGTTA AACTGA TGATTT GATTTC AAATGC AG - 3’ as a reverse primer. The 
resulting 400 bp fragment encompassing the amino acids 343-365 of Nurrr1 fused in 
frame with the N-terminal 100 amino acids of ZPF-10 containing the KRAB 
transcriptional repressor domain was digested with Bam HI and Xho I and ligated 
together with a 1477 bp Spe I/Bam HI fragment from MSCV-Ndelta94Nurr1 comprising 
amino acids 94-365 of Nurr1 into the MSCV-GFP vector digested with Spe I and Xho I. 
 
2.7 ER-caCRTC2: To insert wild type FLAG-tagged murine CRTC2 into the MSCV-
GFP retroviral expression vector, the pcDNA3-FLAG-TORC2 construct (Addgene) was 
used in a PCR reaction together with 5’ - CTCAGA TCTACC ATGGAC TACAAG 
GACGAC GATGA C - 3’as the forward primer and 5’ - GAGCTC GAGTCA TTGGAG 
CCGGTC ACTGCG GAATGA CTCC - 3’ as the reverse primer. The resulting PCR 
fragment was digested with Bgl II and Xho I and ligated into Bgl II/Xho I-digested 
MSCV-GFP. 
The constitutively active CRTC2 mutant containing serine to alanine substitution 
at amino acids 171 and 275 was generated using the mutagenic primers 5’ - CACTTA 
ACAGGA CAAGCG CTGACT CTGCTC TTCAC - 3’ and 5’ - AACACA GGAGGC 
GCCCTA CCTGAC C - 3’ together with the QuickChange II site-directed mutagenesis 
kit from Stratagene. The tamoxifen-regulated conditionally active CRTC2 mutant was 
created by first performing a PCR reaction with a plasmid encoding the tamoxifen-
regulated mutant version of murine estrogen receptor as template and 5’ - CTCGGA 
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TCCACC ATGGAC TACAAG GACGAC GATGAC AAGCTG CAGGAT CCATCT 
GCTGGA GACATG AGGGCT GC - 3’ as forward primer and 5’ - GAGGAA TTCGAT 
CGTGTT GGGAAG CCCTC TGCT - 3’ as the reverse primer. The resulting 900 bp 
fragment was digested with Bam HI and Eco RI and ligated into Spe I/Eco RI-digested 
MSCV-caCRTC2 together with a 700 bp Spe I-Bgl II fragment from MSCV-GFP. 
 
2.8 YFP-CRTC2: To generate an YFP-CRTC2 construct, pEYFP-C1 was used as a 
template in a PCR reaction with 5’ - CTCAGA TCTGCC ACCATG GTGAGC 
AAGGGC GAGGAG CTG - 3’ as forward primer and 5’ - GAGGAA TTCGGA 
TCCGAG TCCGGA CTTGTA CAGCTC GTCCATG - 3’ as reverse primer. The 
resulting 729 bp fragment was digested with Bgl II and Eco RI and ligated together with 
an Eco RI/Xho I-digested 2152 bp fragment of wtCRCT2 into Bgl II/Sal I-digested 
MSCV-GFP. 
 
2.9 K-CREB and CREB R314A: To generate MSCV-CREB, a plasmid encoding rat 
CREB (kind gift from Dr. Basabi Rana, Loyola University Chicago) was used as a 
template in a PCR reaction together with 5’ - CTCCTC GAGACC ATGACC ATGGAC 
TCTGGA GCAGAC AACCAG - 3’ as a forward primer and 5’ - GAGGAA TTCTTA 
ATCTGA CTTGTG GCAGTA AAGGTC - 3’ as reverse primer and the resulting 1034 
bp PCR fragment was digested with Xho I and Eco RI and ligated into Xho I/Eco RI-
digested MSCV-GFP. The dominant-negative K-CREB mutant was generated by PCR 
mutagenesis using the primers 5’- GCAAGA GAATGT CTTATA AAGAAG AAAG - 
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3’ and 5’ - CTTTCT TCTTTA TAAGAC ATTCTC TTGC - 3’ together with the primers 
listed above to introduce the R288L/R289I substitutions into the wtCREB sequence. 
CREB-R314A was generated by a similar strategy using the primers 5’ - GAAAGA 
ATATGT GAAATG TTTAGA GAACGC AGTGGC AGTGCT TG - 3’ and 5’ - 
CAAGCA CTGCCA CTGCGT TCTCTA AACATT TCACAT ATTCTT TC - 3’. 
 
The integrity of all constructs was confirmed by DNA sequence analysis. 
 
3. Retroviral generation and infection of 3T3-L1 cells: Retroviral expression vectors 
were co-transfected with pVSV-G (Clontech) into the GP293 pantropic packaging cell 
line (Clontech) using Lipofectamine Plus (Invitrogen). Media was replaced after 24 h and 
viral supernatants were collected after 24 h and 48 h post-transfection and stored             
at -80ºC. For retroviral infections, 5x104 3T3-L1 cells were plated per well of a 6-well 
plate, the next day media was replaced with retroviral particle-containing growth media 
supplemented with 8 µg/ml polybrene (Sigma) and the plates were centrifuged in a 
swinging bucket rotor at 1,000 rpm for 90 min at room temperature, then returned to the 
incubator overnight. After 24 h, cells were subjected to a second round of infection, 
essentially as described above, then expanded in regular growth medium prior to seeding 
for subsequent experiments.  
 
4. Immunoblot analysis: Whole cell lysates were prepared by adding boiling SDS 
sample buffer (120 mM Tris-HCl pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol) 
directly to cells on the plate. The cell lysates were collected by scraping and boiled for 10 
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min, then sonicated for 10s using a Digital sonifier (Branson) at an amplitude of 11% and 
stored at -80° C. An equal amount of protein from each treatment was resolved by SDS-
PAGE gel electrophoresis, transferred to nitrocellulose membrane, and subjected to 
immunoblot analysis with the following primary antibodies: anti-STAT1 (#9172), anti-
phospho-STAT1 (Tyr701; #9171), anti-STAT3 (#9132), anti-phospho-STAT3 (Tyr705; 
#9131), anti-C/EBPβ (LAP) (#3087), anti-C/EBPδ (#2318) and anti-C/EBPα (#8178) 
from Cell Signaling Technologies; anti-PPARγ (sc-7196), anti-phospho ERK and anti-
ERK (sc-93) from Santa Cruz Biotechnology; anti-aP2 (#10004944) from Cayman 
Chemical Company; anti-mouse EpoR (#AF1390) and anti-Nurr1 (AF2156) from R&D 
systems. Appropriate horseradish peroxidase-conjugated secondary antibodies (anti-
rabbit, anti-mouse, anti-goat) were purchased from Vector laboratories, and detected by 
enhanced chemiluminescence using ECL reagent (Thermo Scientific). 
 
5. Quantitative Real-time PCR (qRT-PCR) analyses: Total RNA was isolated from 
3T3-L1 cells at 48 h post-differentiation using an RNeasy kit (Qiagen). cDNA was 
synthesized from 1 µg of mRNA using random primer and reverse transcriptase 
(Promega). The expression of the relevant genes was determined by qRT-PCR using a 
SYBR Green-based detection system (SA Biosciences) and hypoxanthine 
phosphoribosyltransferase (HPRT) gene as an internal control for normalization. The 
primers used are shown in Table.1. All qRT-PCR measurements were performed using an 
iCycler real-time PCR detection system (Bio-Rad) and the fold change in mRNA 
expression was determined by the ∆∆CT method. 
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6. Enzyme-linked immunosorbent assay (ELISA): Cell culture supernatants were 
collected at the indicated time post-induction of adipocyte differentiation and assayed by 
ELISA for the presence of IL-11 (Cat. No. DY418, R&D Systems) according to the 
manufacturer’s instructions. 
 
7. Immunoflourescence: 3T3-L1 preadipocytes were infected with YFP-CRTC2 
encoding retroviruses as described earlier and induced to undergo adipogenesis using 
standard MDI-induced differentiation protocol in the presence of MDI alone, PGF2α (25 
nM) or PGF2α (25 nM) plus CsA (1 µg/ml). At the indicated time points, cells were fixed 
with 3.7% formalin for 15 min at room temperature and then, washed 3 times with PBS. 
The cells were permeabilized with 0.05% saponin in PBS and then, washed 3 times with 
PBS. Then, the cells were incubated in dark with DAPI (0.5 µg/ml) in PBS for 10 min at 
room temperature and then, washed 3 times with PBS. To keep the cells wet, 2 ml of PBS 
was added to each well. The cells were examined and counted using fluorescence 
microscopy (Olympus Inc, Center Valley, PA). At least 100 cells expressing YFP-
CRTC2 were counted per well and classified as cells with YFP-CRTC2 either completely 
nuclear, completely cytoplasmic, more nuclear than cytoplasmic and more cytoplasmic 
than nuclear. Then, the cells with YFP-CRTC2 completely nucleus and more nuclear than 
cytoplasm were grouped as nuclear, whereas with completely cytoplasmic and more 
cytoplasmic than nuclear were grouped as cytoplasmic. 
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8. Luciferase assay: HEK293T cells were plated at the concentration of 5x104 cells per 
well in 24 well plates. Next day, the cells were transfected with plasmids encoding either 
GFP, Nurr1-WT (100 ng/well) or DN-Nurr1 (0, 100, 200 and 400 ng/well) as indicated 
along with appropriate amount of GFP control plasmid to make the final concentration of 
plasmids to 500 ng/well. Simultaneously, the cells were also transfected with the Nurr1 
reporter, (NBRE)3-TK-LUC (Firefly; 50 ng/well) and pRG-TK (Renilla; 25 ng/well) 
reporter plasmids. The transfection was performed using Attractene transfection reagent 
(Qiagen, Cat. No. 301005) following manufacturer’s instructions. At 24 h post-
transfection, Luciferase bioluminescence for each well was determined using Dual-
luciferase reporter assay system (Promega, Cat. No. E1910) following the manufacturer’s 
instructions and TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA). Firefly 
luciferase activity of each well was corrected using the corresponding Renilla luciferase 
activity as a transfection efficiency control. The fold effect of (NBRE)3 activation by 
DN-Nurr1 was determined with comparison to that of Nurr1-WT expression alone. 
 
To determine the activation of ER-caCRTC2, HEK293T cells were plated as 
described above and next day, the cells were transfected with either GFP or ER-
caCRTC2 plasmids at the concentration of 400 ng/well along with the CREB reporter, 
CRE-Luc (Firefly; 50 ng/well) and pRG-TK (Renilla; 25 ng/well) reporter plasmids as 
described above. At 16 h post-transfection, cells were treated with either vehicle or 
tamoxifen (500 nM). Cells were lysed at 4 h post-treatment and luciferase activity was 
measured as described above. 
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9. Statistical analysis: The data are expressed as the mean ± S.E.M. For comparison 
between groups, either one-way ANOVA followed by Bonferroni post hoc test or 
Student’s t test was employed. Differences were considered to be statistically significant 
at p < 0.05. 
 
TABLE 1. Nucleotide sequence of primers used for qRT-PCR 
Gene Forward Primer Reverse Primer 
Il-11 5’-CTGTGGGGACATGAA CTGTG-3’ 
5’-CGTCAGCTGGGAATT 
TGTCT-3’ 
Il-6 5’-AGTTGCCTTCTTGGGA CTGA-3’ 
5’-TCTGCAAGTGCATCAT 
CGTT-3’ 
Hprt 5’-GTTGGATACAGGCCA GACTT TGTTG-3’ 
5’-GAGGGTAGGCTGGCC 
TATAGGCT-3’ 
Nurr1 5’-CGGTTTCAGAAGTGCC TAGC-3’ 
5’-TTGCCTGGAACCTGGA 
ATAG-3’ 
Nur77 5’-ATGCCTCCCCTACCAA TCTT-3’ 
5’-TCTGCCCACTTTCGGAT 
AAC-3’ 
Nor1 5’-CCAAACCAAAGAGCCC ACTA-3’ 
5’-GGCCGTCAGAAGGTTG 
TAGA-3’ 
 5’-CTGCCTTCCAAACCAA AGAG-3’ 
5’-GGCCGTCAGAAGGTTG 
TAGA-3’ 
 5’- TCAGCCTTTTTGGAG CTGTT-3’ 
5’-TAACCCATGTCGCTCT 
GTGA-3’ 
 5’-AGAACGGTGCAGAAAA ATGC-3’ 
5’-TAGTGGGCTCTTTGGT 
TTGG-3’ 
Crtc1 5’-CACCAGAGCACAATGA CACC-3’ 
5’-GCCTTCTTTGAGTCCC 
ATGA-3’ 
Crtc2 5’-TGGATGCTAAAGTCCC TGCT-3’ 
5’-TAGCAGGCTGGTCAGG 
AGAT-3’ 
Crtc3 5’-TTCCAGCCATCACTTC ATCA-3’ 
5’-AGCTCTCATCCAGGTG 
CTGT-3’ 
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CHAPTER III 
THE PGF2α/CALCINEURIN-SIGNALING PATHWAY INHIBITS 
ADIPOGENESIS VIA AN AUTOCRINE/PARACRINE-MEDIATED                     
IL-11/GP130/STAT1-DEPENDENT SIGNALING CASCADE
 
1. Introduction: Adipocytes are specialized cells that form adipose tissue and are known 
to regulate energy homeostasis and whole body metabolism (Rosen and Spiegelman, 
2006). The excessive accumulation of adipose tissue due to hypertrophy and hyperplasia 
of adipocytes contributes to the development of obesity which is associated with co-
morbidities such as insulin resistance, type 2 diabetes, cardiovascular diseases and some 
cancers (De Pergola and Silvestris, 2013; Kahn and Flier, 2000; Kahn et al., 2006; 
Nakamura et al., 2013; Nishimura et al., 2009; Van Gaal et al., 2006). Recent findings 
support that the generation of new insulin-sensitive adipocytes through adipogenesis 
plays a protective role in the development of type 2 diabetes in obesity (Tan and Vidal-
Puig, 2008; Virtue and Vidal-Puig, 2010). However, obesity is considered as an 
inflammatory condition (Gregor and Hotamisligil, 2011) and several inflammatory 
mediators are known to inhibit adipogenesis (Gustafson and Smith, 2006; Xu et al., 
1999). Given the protective role of adipogenesis in the development of obesity associated 
complications, it is important to understand the molecular mechanisms by which these 
inflammatory mediators inhibit adipogenesis to identify better targets to treat obesity and 
the associated complications. An inflammatory mediator that is known to inhibit 
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adipogenesis both in vitro and in vivo is PGF2α (Casimir et al., 1996; Liu and Clipstone, 
2007; Miller et al., 1996; Volat et al., 2012). In our attempts to understand the underlying 
molecular mechanisms, our previous studies showed that PGF2α inhibits adipocyte 
differentiation through activation of the calcium-dependent phosphatase, calcineurin (Liu 
and Clipstone, 2007). In this chapter, we further extended our studies and demonstrate 
that the PGF2α/calcineurin-signaling pathway inhibits adipogenesis through activation of 
an autocrine/paracrine-mediated IL-11/gp130/STAT1- dependent signaling cascade. 
 
2. Interleukin-11 (IL-11) cytokine: IL-11 is a multifunctional cytokine belonging to IL-
6 family of cytokines which also consists of IL-6, LIF (leukemia inhibitory factor), OSM 
(oncostatin M), CNTF (ciliary neurotrophic factor), CT-1 (cardiotrophin-1) and CLC 
(cardiotrophin-like cytokine) (Heinrich et al., 2003; Taga and Kishimoto, 1997).  All 
these family members bind to specific transmembrane, non-signaling α-subunit and 
signal through recruitment of a common β-subunit called glycoprotein 130 (gp130) 
(Heinrich et al., 2003; Taga and Kishimoto, 1997). Though gp130 is ubiquitously 
expressed, expression of specific α-chain determines the tissue specificity of each IL-6 
family members. IL-11 is a peliotrophic cytokine with multiple biological effects 
including hematopoiesis, lymphopoiesis, immune response and cell differentiation 
(Bozza et al., 2001; Du et al., 1993; Suga et al., 2001; Weich et al., 1997). In addition, IL-
11 is over expressed in certain tumors and has been shown to play a role in the 
development and metastasis of certain tumors (Grivennikov, 2013; Onnis et al., 2013). 
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2.1 IL-11 signaling: IL-11 signals through a hexameric receptor complex consisting of 
two molecules each of ligand-binding IL-11 α-subunit (IL-11Rα) and the gp130 co-
receptor β-chain signaling receptor (Barton et al., 2000). The IL-11Rα subunit lacks 
intrinsic signaling capacity, however, binding of IL-11 to IL-11Rα promotes the 
formation of a complex with gp130 and subsequent gp130 heterodimerization, thereby 
allowing the activation of the gp130-associated JAK kinases and phosphorylation of 
critical conserved tyrosine residues within the gp130 cytoplasmic domain that are 
responsible for the recruitment and activation of specific downstream signaling molecules 
(Heinrich et al., 2003; Taga and Kishimoto, 1997). Specifically, phosphorylation of Y759 
within the gp130 cytoplasmic domain forms a docking site for the SHP2 adaptor protein 
that is responsible for triggering the activation of the Ras-Raf-mitogen-activated protein 
kinase (MAPK) signaling pathway, whereas phosphorylation of Y767, Y814, Y905 and 
Y915 results in the recruitment of STAT1 and STAT3 to gp130. Once recruited to the 
receptor complex, STAT1 and STAT3 are phosphorylated by JAKs and then, they homo 
and/or hetrodimerize, translocate to the nucleus and regulate gene expression (Figure 3) 
(Heinrich et al., 2003).  
 
2.2 Role of IL-11 in inhibiting adipogenesis: IL-11 was initially cloned as an 
adipogenesis inhibitory factor (AGIF) from human bone-marrow derived stromal cell line 
as the supernatant collected from the COS-1 cells that overexpress AGIF cDNA inhibited 
differentiation of 3T3-L1 cells into adipocytes and thus, provided initial evidence that  
IL-11 is a potent inhibitor of adipocyte differentiation (Kawashima et al., 1991).  
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FIGURE 3. Schematic model showing the IL-11/gp130-dependent signaling 
pathways.  
 
 
IL-11 binds to non-signaling α chain and recruits signaling subunit, gp130 co-receptor. 
Then, the JAKs associated with gp130 phosphorylate specific tyrosine residues in the 
cytoplasmic domain of gp130, resulting in the recruitment of STATs, which are then 
phosphorylated by JAKs, homo/heterodimerize, translocate to nucleus and induce gene 
expression.  
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In human long-term marrow culture that has a potential to differentiate into myeloid cells 
and adipocytes, IL-11 inhibited these cells to differentiate into adipocytes, whereas 
promoted them to differentiate into hematopoietic cells (Keller et al., 1993). This further 
provided evidence that IL-11 is a potent inhibitor of adipogenesis in hematopoietic 
microenvironment. Further, IL-11 secreted by breast tumor cells inhibited the 
differentiation of fibroblast into adipocytes (Meng et al., 2001). Thus, several studies 
using cell culture system show that IL-11 inhibits adipogenesis. The physiological role of 
IL-11 in regulating adipogenesis is evident from the analysis of the P6 strain of 
senescence-accelerated mice (SAMP6). These mice showed a decrease in 
osteoclastogenesis and osteoblastogenesis, whereas they showed increased adipose tissue 
in bone marrow compared to control mice (Kajkenova et al., 1997). Further analysis of 
the bone marrow stromal cells from these mice showed a decreased expression of IL-11 
and an increased potential to differentiate into adipocytes (Kodama et al., 1998). Further, 
transgenic mice with IL-11 overexpression showed a significantly increased bone mass 
and cortical thickness, suggesting that IL-11 promotes osteoblastogenesis (Takeuchi et 
al., 2002). These findings show that IL-11 physiologically inhibits adipocyte 
differentiation, whereas promotes osteoblast differentiation. Collectively, therefore, 
multiple evidence support that IL-11 is a potent inhibitor of adipocyte differentiation. 
However, the precise molecular mechanisms and downstream signaling pathways 
involved in mediating the inhibitory effects of IL-11 on adipogenesis are not known. 
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3. STAT transcription factors: The STAT proteins are a family of latent cytoplasmic 
transcription factors that consist of STAT1, STAT2, STAT3, STAT4, STA5a, STAT5b 
and STAT6. These proteins are activated by interferons, IL-6 family of cytokines, growth 
hormone, erythropoietin, leptin and others (Brierley and Fish, 2005). Binding of these 
factors to their cognate receptors activate JAKs, which inturn phosphorylate specific 
tyrosine residues in the cytoplasmic tail of the receptor to generate docking sites for 
STAT proteins and subsequently, STATs are recruited to the receptor complex (Fu et al., 
1992; Platanias et al., 1994; Schindler et al., 1992). Once recruited to the receptor 
complex, STAT proteins are phosphorylated by JAKs and then, they homo or 
heterodimerize, transloacte to nucleus and induce gene expression (Darnell, 1997). The 
genes induced by these STAT transcription factors are known to regulate various 
biological and pathological process including cell growth and differentiation, 
metabolism, hematopoiesis, host defense, immunoregulation and cancer development 
(Bromberg and Darnell, 2000; O'Shea et al., 2013; Xu et al., 2013).  
 
3.1 Expression of STATs during adipogenesis: Studies with 3T3-L1 cells and human 
subcutaneous preadipocytes showed that several STAT proteins are expressed and 
regulated during adipogenesis (Harp et al., 2001; Stephens et al., 1996). STAT1, STAT3 
and STAT5 proteins are minimally expressed in undifferentiated 3T3-L1 cells, whereas 
their expression significantly increases after adipogenic stimulation. While STAT3 
expression remains at the same level, STAT1 and STAT5 expression decreases after 24 h 
of induction and again increases after 96 h. Further, STAT6 is expressed at high level in 
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preadipocytes and the level of expression remains constant during adipogenic process. In 
contrast, STAT2 and STAT4 are not expressed in preadipocytes (Stephens et al., 1996). 
Although several STAT family members are expressed during adipogenesis, STAT5 has 
extensively been studied and has been shown to positively regulate adipogenesis (White 
and Stephens, 2010). Recent evidences show that STAT3 positively regulates 
adipogenesis (Wang et al., 2009; Zhang et al., 2011), whereas STAT1 inhibits 
adipogenesis (McGillicuddy et al., 2009) which is discussed below. 
 
3.2 Role of STAT3 in adipogenesis: While STAT3 level remains constant throughout 
adipogenesis, it is highly phoshorylated and translocated into nucleus within 2 h of 
adipogenic stimulation. This phosphorylation seems to be regulated by JAK2 as both the 
inhibitor of JAK2/STAT3 activation, AG490 and depleting JAK2 expression using 
siRNA decrease the STAT3 phosphorylation during adipogenesis (Wang et al., 2009). 
Initial studies linked the early phosphorylation and activation of STAT3 to cell 
proliferation and mitotic clonal expansion phase of adipogenesis (Deng et al., 2000). 
Further, STAT3 has been shown to bind to DNA during this phase. Later studies showed 
that STAT3 directly bind to C/EBPβ promoter during the early stages of adipogenesis 
and regulates its expression (Zhang et al., 2011). This is a highly possible mechanism as 
multiple evidence shows that C/EBPβ plays an important role in the regulation of critical 
mitotic clonal expansion phase of adipogenesis (Tang et al., 2003a).  Further evidence for 
the role of STAT3 in adipogenesis is evident from the findings that the expression of a 
dominant-negative STAT3 and knockdown of STAT3 expression using siRNA blocks 
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adipogenesis (Wang et al., 2009). Collectively, STAT3 plays a positive role in 
adipogenesis by regulating C/EBPβ expression and mitotic clonal expansion.   
 
 3.3 Role of STAT1 in adipogenesis: The activation of STAT1 appears to inhibit 
adipocyte differentiation as the stimulation of adipogenesis in the presence of INFγ, a 
potent activator of STAT1, inhibits adipogenesis (McGillicuddy et al., 2009). In mature 
adipocytes, INFγ treatment resulted in strong activation and nuclear translocation of 
STAT1 which correlated with a substantial decrease in PPARγ expression (Waite et al., 
2001). Further studies identified a potential consensus sequence of interferon-γ-activated 
site (GAS) elements in the PPARγ2 promoter and indeed, STAT1 homodimers are shown 
to bind an IFNγ-responsive site within the PPARγ2 promoter in 3T3-L1 cells (Hogan and 
Stephens, 2001). Collectively, the available evidence suggests that activation of the 
STAT1 transcription factor inhibits adipogenesis through possibly inhibiting the 
expression of PPARγ. 
 
4. Role of ERK in adipogenesis: ERK has been shown to both positively and negatively 
regulate adipocyte differentiation. While ERK has been shown to positively regulate 
adipogenesis by phosphorylating C/EBPβ during the early stage of adipogenesis (Tang et 
al., 2005), angiotensin-mediated activation of ERK has been shown to inhibit adipocyte 
differentiation (Fuentes et al., 2010). Further, mechanical stretch induced activation of 
ERK has been shown to inhibit adipogenesis through down regulation of PPARγ 
expression (Tanabe et al., 2004). Thus activation of ERK during early stage of 
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differentiation promotes adipogenesis, whereas its activation in the later stage inhibits 
adipogenesis by blocking PPARγ expression. 
 In this chapter, we investigated the role IL-11 in mediating the inhibitory effects 
of PGF2α on adipogenesis. First, we show that PGF2α induces IL-11 expression during 
adipogenesis in a calcineurin-dependent mechanism. Next, using IL-11 specific shRNA 
and a dominant-negative gp130, we demonstrate that IL-11/gp130-mediated signaling is 
required for the inhibitory effects of PGF2α on adipogenesis. Further, using a panel of 
chimeric, mutant gp130 receptors, we identify that the gp130-mediated activation of 
STAT1 transcription factor inhibits adipogenesis. In addition, using STAT1 specific 
shRNAs, we demonstrate that STAT1 is required for the inhibitory effects of IL-11 and 
PGF2α on adipogenesis. Collectively, our results provide evidence that the 
PGF2α/calcineurin-signaling pathway inhibits adipocyte differentiation through 
activation of an autocrine/paracrine IL-11/gp130/STAT1-dependent signaling. 
 
5. RESULTS 
5.1 Activation of the PGF2α/calcineurin-signaling pathway induces the expression 
of IL-11 in differentiating 3T3-L1 preadipocytes. In previous studies we had 
demonstrated that PGF2α inhibits the early stages of adipocyte differentiation via the 
essential actions of the calcineurin phosphatase (Liu and Clipstone, 2007). Since 
calcineurin is a well-known positive regulator of a number of transcription factor 
(Crabtree, 2001), we hypothesized that the PGF2α/calcineurin-signaling pathway was 
likely to inhibit adipogenesis via the increased expression of a gene(s) capable of  
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FIGURE 4. PGF2α treatment of differentiating 3T3-L1 preadipocytes induces the 
calcineurin-dependent expression and secretion of IL-11.  
 
Two-day post-confluent 3T3-L1 preadipocytes were induced to undergo adipocyte 
differentiation by treatment with MDI in the presence of either vehicle, PGF2α (25 nM) 
alone or PGF2α (25 nM) plus Cyclosporin A (CsA) (1 µg/ml). At 48 h post-stimulation, 
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total RNA and cell culture supernatants were collected and the expression of IL-11 was 
determined by qRT-PCR (A) and ELISA (B), respectively. The expression of IL-6 was 
determined by qRT-PCR (C).  The data is shown as mean ± SEM (either one-way 
ANOVA followed Bonferroni post hoc test or Student’s t test; p<0.05; n=3). ND; not 
detectable. Results are representative of at least three independent experiments. 
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inhibiting the differentiation process. In order to test this hypothesis, we initially 
performed a microarray gene expression profiling experiment to identify candidate anti-
adipogenic genes induced by PGF2α in a calcineurin-dependent fashion during the early 
stages of 3T3-L1 preadipocyte differentiation. Amongst the most highly induced genes 
identified by this analysis was the multifunctional cytokine IL-11. This observation was 
of significant interest, as IL-11 had previously been shown to be a potent inhibitor of 
adipocyte differentiation (Kawashima et al., 1991; Keller et al., 1993).  
To confirm our initial microarray result, we performed quantitative RT-PCR and 
ELISA experiments to analyze the expression of IL-11 in 3T3-L1 cells induced to 
undergo adipocyte differentiation in the presence or absence of PGF2α. As shown in 
Figure 4, while 3T3-L1 preadipocytes induced to undergo adipocyte differentiation by the 
standard MDI-induced protocol expressed essentially undetectable levels of IL-11          
at 48 h-post stimulation, significant levels of both IL-11 mRNA (Fig. 4A) and protein 
(Fig. 4B) were readily observed in cells induced to differentiate in the presence of 
PGF2α, an effect that was attenuated in the presence of the calcineurin-specific inhibitor 
cyclosporin A (CsA). In fact, we observed that treatment of non-differentiated 3T3-L1 
cells with PGF2α alone was sufficient to induce IL-11 expression, although in this case 
the level of induction (~3-fold; data not shown) was significantly less than that observed 
in the presence of the MDI adipogenic cocktail (23-fold; see Fig. 4A). As IL-11 is a 
member of the IL-6 family of cytokines (Taga and Kishimoto, 1997), we also 
investigated whether PGF2α affected the expression of other family members during the 
differentiation process. In this respect, while our initial microarray data and subsequent 
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qRT-PCR analysis revealed that the expression of IL-6 itself was induced by PGF2α 
treatment, the level of induction observed (3.5-fold) was considerably lower compared to 
the effect on IL-11 (Fig. 4C), whereas no substantial effect of PGF2α on the expression 
of other members of this family was observed. Taken together, therefore, our results 
indicate that the activation of the PGF2α/calcineurin-signaling pathway synergizes with 
MDI-induced signals during the early stages of 3T3-L1 preadipocyte differentiation to 
specifically induce the robust expression and subsequent secretion of the IL-11 cytokine, 
which given the known anti-adipogenic effects of IL-11 (Kawashima et al., 1991; Keller 
et al., 1993), raised the possibility that PGF2α might act to inhibit adipogenesis by means 
of an IL-11 mediated autocrine mechanism.  
 
5.2 IL-11 and gp130 cytokine co-receptor-dependent signaling play a role in 
mediating the inhibitory effects of PGF2α on adipocyte differentiation. Since IL-11 
signaling is known to be critically dependent upon the actions of the gp130 cytokine co-
receptor signaling subunit (Barton et al., 2000), we initially took advantage of a well-
characterized dominant-negative form of gp130 (DN-gp130) (Kumanogoh et al., 1997) to 
examine the potential role of IL-11 in mediating the inhibitory effects of the 
PGF2α/calcineurin-signaling pathway on adipocyte differentiation. This dominant-
negative gp130 mutant comprises the extracellular domain of gp130 known to be 
responsible for interacting with IL-11/IL-11Rα complexes, but lacks the cytoplasmic 
domain containing the conserved residues required for signal transduction. Consequently, 
ectopic expression of DN-gp130 should act to attenuate gp130-dependent signaling  
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FIGURE 5. gp130-dependent signaling play a role in mediating the inhibitory effects 
of PGF2α on adipocyte differentiation.  
 
 
3T3-L1 preadipocytes transduced with either MSCV-GFP or MSCV-DN-gp130 
retroviruses were induced to undergo differentiation with MDI in the presence of the 
indicated concentrations of PGF2α for the initial 48 h and the extent of adipocyte 
differentiation was determined at day 8 by either ORO staining (A) or immunoblotting 
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for the expression of PPARγ and aP2 (B). Equal protein loading was confirmed by 
probing with a control antibody directed against ERK. Results are representative of at 
least three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
events by sequestering IL-11 in non-functional complexes incapable of signaling. Thus, 
to initially establish the potential role of gp130 signaling in mediating the inhibitory 
effects of PGF2α on adipocyte differentiation, 3T3-L1 preadipocytes were transduced 
with either a control retrovirus or a retrovirus encoding DN-gp130, and then induced to 
undergo differentiation by the standard MDI-induced adipogenic protocol in the presence 
of various concentrations of PGF2α. As expected, the graded doses of PGF2α served to 
produce a potent dose-dependent inhibition of adipocyte differentiation in control cells, 
as measured by a decrease in cells staining positive for Oil Red O (ORO) (Fig. 5A) and 
the decreased expression of the adipocyte-specific genes PPARγ and aP2 (Fig. 5B). In 
contrast, we found that ectopic expression of DN-gp130 was able to greatly attenuate the 
inhibitory activity of PGF2α, allowing 3T3-L1 preadipocyte cells to differentiate in the 
presence of concentrations of PGF2α that were able to potently inhibit the differentiation 
of control cells (Figs 5A, B). This result demonstrates that inhibiting gp130-dependent 
signaling in 3T3-L1 preadipocytes is able to partially rescue adipocyte differentiation in 
cultures containing PGF2α, thereby suggesting a critical role for gp130 signaling in 
mediating the inhibitory effects of PGF2α on adipocyte differentiation.  
While the gp130 cytokine co-receptor signaling subunit is an essential component 
of the IL-11 receptor (Barton et al., 2000), it is also known to be involved in mediating 
the signaling of other members of the IL-6 family of cytokines (Heinrich et al., 2003; 
Taga and Kishimoto, 1997). Consequently, to more directly assess the role of IL-11 in  
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FIGURE 6. IL-11 play a role in mediating the inhibitory effects of PGF2α on 
adipocyte differentiation.  
 
 
(A, B) 3T3-L1 preadipocytes transduced with retroviruses encoding either control or IL-
11-specific shRNA were induced to undergo differentiation with MDI in the absence or 
presence of PGF2α (12.5 nM) for the initial 48 h. After 8 days, the extent of adipocyte 
differentiation was assessed by ORO staining (A) or immunoblotting for the expression 
of PPARγ and aP2 (B). Equal protein loading was confirmed by probing with a control 
antibody directed against ERK. (C) The efficiency of knockdown of IL-11 mRNA was 
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determined by qRT-PCR using RNA isolated from PGF2α-treated cells at the 48 h time 
point. The data is shown as mean ± SEM (One-way ANOVA followed by Bonferroni 
post hoc test; p<0.05; n=3). Results are representative of at least three independent 
experiments. 
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mediating the inhibitory effects of PGF2α on adipocyte differentiation, we adopted a 
shRNA-mediated knockdown strategy in which 3T3-L1 preadipocytes were transduced 
with retroviruses encoding either a control shRNA or an shRNA-specific for IL-11, then 
subsequently examined for their ability to undergo adipocyte differentiation in the 
presence of an inhibitory concentration of PGF2α (12.5 nM). As expected, the ability of 
control shRNA-transduced 3T3-L1 preadipocytes to undergo adipocyte differentiation 
under these conditions was potently inhibited, as determined by both loss of ORO-
staining cells and decreased expression of PPARγ and aP2 (Fig. 6A, B). Conversely, in 
IL-11 specific shRNA-transduced cultures induced to undergo differentiation in the 
presence of this same inhibitory concentration of PGF2α, we consistently observed the 
rescue of adipocyte differentiation, as indicated by the presence of significant patches of 
ORO-staining cells and the expression of both PPARγ and aP2 (Fig. 6A, B). In these 
experiments we found that the IL-11 specific shRNA was typically able to reduce the 
level of IL-11 induced in PGF2α-treated 3T3-L1 preadipocytes by approximately 70% 
compared to control shRNA-expressing cells (see Fig. 6C). These results therefore 
provide evidence that IL-11 likely plays an important role in mediating the inhibitory 
effects of the PGF2α/calcineurin-signaling pathway on adipocyte differentiation and are 
consistent with a model in which PGF2α-induces the initial expression and subsequent 
secretion of IL-11, which then acts in an autocrine/paracrine fashion to inhibit adipocyte 
differentiation by means of a gp130 cytokine co-receptor-dependent pathway. 
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FIGURE 7. Schematic model illustrating the chimeric EpoR/gp30 receptors used in 
this study.  
 
 
The array of chimeric EpoR/gp130 receptors used in this study comprising of the 
extracellular ligand-binding domain of the EpoR (grey ovals) fused to various amino 
acid-substituted versions of the intracellular domain of gp130 (open rectangles) are 
shown. The position of the conserved tyrosine residues in the gp130 cytoplasmic domain 
and corresponding tyrosine to phenylalanine substitutions are indicated, as are the 
synthetic peptide sequences used for the selective activation of STAT1 and STAT3 in the 
EG-4F-STAT1 and EG-4F-STAT3 “add-back” mutants. 
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FIGURE 8. gp130-dependent signaling is sufficient to inhibit adipocyte 
differentiation.  
 
 
3T3-L1 preadipocyte cells were initially infected with either MSCV-GFP or MSCV-EG-
WT retroviruses then super-infected with either MSCV-DsRed or MSCV-DsRed-PPARγ 
retroviruses, as indicated. (A) The expression of EG-WT and PPARγ was confirmed by 
immunoblotting with antibodies specific for EpoR and PPARα, while equal protein 
loading was confirmed by immunoblotting with a control antibody directed against ERK. 
(B, C) Two-day post-confluent cells were then induced to differentiate with MDI in the 
presence or absence of Epo for the initial 48 h and the degree of adipocyte differentiation 
was assessed at day 8 post-stimulation by ORO staining (B) and immunoblotting for the 
expression of PPARγ and aP2 (C). Equal protein loading was confirmed by probing with 
a control antibody directed against ERK. Results are representative of more than three 
independent experiments. 
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5.3 gp130 cytokine co-receptor-dependent signaling is sufficient to inhibit adipocyte 
differentiation by blocking the expression of PPARγ. Next, we determined whether 
gp130 signaling per se was sufficient to inhibit adipocyte differentiation. For this 
experiment, we took advantage of a previously characterized chimeric form of gp130 in 
which the cytoplasmic signaling domain of gp130 is fused to the extracellular ligand-
binding domain of the erythropoietin receptor  (EpoR/gp130; EG-WT; see Fig. 7), which 
allows gp130-specific signaling events to be induced in response to stimulation with 
erythropoietin (Epo) (Schaper et al., 1998; Schmitz et al., 2000). As shown in Fig. 8, the 
presence of Epo in the culture medium had no effect on the ability of control GFP-
expressing cells to undergo adipocyte differentiation, but conversely was able to potently 
inhibit the differentiation of cells ectopically expressing the EG-WT chimeric receptor, as 
measured by a decrease in both ORO staining and the expression of PPARγ and aP2 (Fig. 
8B, C). Furthermore, we found that ectopic expression of PPARγ in cells expressing the 
EG-WT chimeric receptor was able to bypass the inhibitory effects of Epo on adipocyte 
differentiation in these cells (Fig. 8B, C). Taken together, these data indicate that gp130 
signaling per se is sufficient to inhibit adipocyte differentiation, most likely by acting to 
block the expression of the pro-adipogenic master regulatory transcription factor, PPARγ.  
 
5.4 C-terminal tyrosine residues involved in the activation of STAT transcription 
factors play a critical role in mediating the inhibitory effects of gp130 signaling on 
adipocyte differentiation. Signaling via gp130 is critically dependent upon conserved 
tyrosine residues located within the cytoplasmic domain, which are phosphorylated in  
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FIGURE 9. Tyrosine residues involved in STAT transcription factor activation play 
a role in mediating the inhibitory effects of gp130-dependent signaling on adipocyte 
differentiation.  
 
 
(A) 3T3-L1 preadipocyte cells were infected with either MSCV-GFP, EG-WT, EG-1F, or 
EG-4F encoding retroviruses and the expression of each chimeric receptor was 
determined by immunoblotting with an antibody specific for EpoR, while equal protein 
loading was confirmed by immunoblotting with a control antibody directed against ERK. 
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(B) To confirm the ability of the chimeric receptors to activate STAT1 and STAT3, 
whole cell extracts from cells induced to differentiate with MDI in the presence of Epo 
were analyzed by immunoblotting at the indicated times with antibodies specific for 
pSTAT1-Y701, STAT1, pSTAT3-Y705, and STAT3. (C) To determine the activation of 
ERK by the chimeric receptors, whole cell extracts from 90% confluent cells treated with 
Epo in serum free medium were collected at the indicated time and analyzed by 
immunoblotting with antibodies specific for pERK and ERK.  (D, E) Two-day post-
confluent cells were induced to differentiate with MDI in the presence of Epo for the 
initial 48 h. After 8 days, adipocyte differentiation was assessed by ORO staining (C) and 
immunoblotting for the expression of PPARγ and aP2 (D). Results are representative of 
more than three independent experiments. 
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response to receptor activation and are responsible for recruiting cytoplasmic signaling 
molecules involved in the propagation of specific downstream signaling pathways 
(Heinrich et al., 2003; Taga and Kishimoto, 1997). IL-11 signaling mediated via the 
gp130 co-receptor signaling subunit is known to primarily activate two independent 
downstream effectors pathways: the ERK and JAK/STAT signaling pathways (Heinrich 
et al., 2003; Taga and Kishimoto, 1997). In order to ascertain which of these gp130-
dependent signaling events were responsible for mediating the inhibition of adipocyte 
differentiation, we took advantage of previously well-characterized EpoR/gp130 chimeric 
mutants known to be selectively deficient in the activation of one or another of these 
signaling pathways (Schaper et al., 1998; Schmitz et al., 2000). Specifically, we utilized 
chimeric mutant receptors with either a Y759F substitution (EG-1F) that is known to be 
selectively deficient in the activation of the downstream ERK pathway, or a quadruple 
chimeric mutant receptor containing Y767F, Y814F, Y905F and Y915F substitutions 
(EG-4F) that is selectively deficient in the activation of the STAT1 and STAT3 latent 
transcription factors (see Fig. 7 for details). Each of these mutant receptors, along with 
EG-WT, was independently introduced into 3T3-L1 preadipocytes by retroviral 
transduction, and immunoblot analysis was performed to confirm that each receptor was 
expressed at comparable levels (Fig. 9A). Subsequently, cells were then induced to 
undergo adipocyte differentiation by the standard MDI-induced protocol in either the 
presence or absence of Epo, and the effects on differentiation were assessed. As shown in 
Figure 9D and E, the presence of Epo was able to inhibit the differentiation of EG-1F-
expressing cells to essentially the same degree as that observed for cells expressing EG-
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WT. By contrast, the presence of Epo had no effect on the ability of EG-4F expressing 
cells to differentiate. As shown in Figure 9B, immunoblot analysis confirmed that unlike 
EG-WT and EG-1F, the EG-4F receptor was deficient in its ability to efficiently activate 
STAT1 and STAT3 in response to Epo stimulation. Further, as shown in Figure 9C, 
unlike EG-4F, the EG-1F receptor was deficient in its ability to activate ERK. These data 
therefore demonstrate that the four C-terminal tyrosine residues present in the 
cytoplasmic domain of gp130 are required for the gp130-mediated inhibition of adipocyte 
differentiation. Moreover, since these latter tyrosine residues are required for the gp130-
mediated activation of STAT1 and STAT3, the data further suggests a potentially 
important role for the activation of STAT transcription factors in mediating the inhibitory 
effects of gp130 co-receptor signaling on adipocyte differentiation. 
 
5.5 A critical role for STAT1 in mediating the inhibitory effects of gp130, IL-11 and 
PGF2α on adipocyte differentiation. To further examine the potential role of STAT1 
and STAT3, we next generated chimeric gp130 “add-back” receptors in which consensus 
peptide sequences previously reported to selectively activate either STAT1 or STAT3 
(Gerhartz et al., 1996) were fused in-frame to the C-terminus of STAT signaling-deficient 
EG-4F mutant receptor, thereby generating EG-4F-STAT1 and EG-4F-STAT3, 
respectively (see Fig. 7). Each of these mutant “add-back” receptors, along with the 
parental EG-4F receptor, was independently expressed in 3T3-L1 preadipocytes (Fig. 
10A) and their ability to activate STATs (Fig. 10B) and inhibit adipocyte differentiation 
(Fig. 10C, D) was assessed. As shown in Figure 10B, Epo-treatment of cells expressing  
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10. gp130-dependent selective activation of STAT1, but not STAT3 inhibits 
adipocyte differentiation.  
 
 
(A) 3T3-L1 preadipocyte cells were infected with either EG-4F, EG-4F-STAT1 or EG-
4F-STAT3 encoding retroviruses and their expression was assessed by immunblotting the 
whole cell extracts with an antibody specific for EpoR, and ERK as a control for equal 
protein loading. (B) To determine the activation selectivity of the chimeric add-back 
receptors, the above cells were induced to differentiate with MDI in the presence of Epo 
and whole cell extracts prepared at the indicated times were analyzed by immunoblotting 
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with antibodies specific for pSTAT1-Y701, STAT1, pSTAT3-Y705 and STAT3. (C, D) 
Two-day post-confluent cells from (A) were induced to differentiate with MDI in the 
presence of Epo and after 8 days, the extent of adipocyte differentiation was assessed by 
ORO staining (C) and immunoblotting for the expression of PPARγ and aP2 (D). Results 
are representative of more than three independent experiments. 
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the EG-4F-STAT1 mutant receptor resulted in the preferential activation of STAT1, 
whereas Epo-stimulation of EG-4F-STAT3-expressing cells led to the preferential 
activation of STAT3. We note that although the EG-4F receptor is completely deficient in 
its ability to activate STAT1, it is still able to induce residual levels of STAT3 activation, 
albeit considerably reduced compared to EG-WT (see Fig 10B). Based upon analysis of 
mutant receptors lacking all cytoplasmic tyrosine residues, we believe that this effect is 
likely due to the ability of gp130-associated JAK2 to very inefficiently activate parallel 
gp130-independent pathways leading to STAT3 activation (data not shown). 
Nonetheless, it is clear from our data that EG-4F-STAT1 and EG-4F-STAT3 
preferentially activate STAT1 and STAT3, respectively. When 3T3-L1 preadipocytes 
expressing these mutant receptors are induced to differentiate in the presence of Epo, we 
find that only those cells expressing EG-4F-STAT1 are blocked from undergoing 
adipogenesis, as measured by a decrease in both ORO staining (Fig. 10C) and the 
expression of PPARγ and aP2 (Fig. 10D). These data therefore suggest that it is the 
activation of the STAT1 transcription factor, rather than STAT3, that is associated with 
the ability of gp130 to inhibit adipocyte differentiation.  
In order to further define the role of STAT1 as a critical anti-adipogenic effector 
of the gp130-signaling pathway, we next chose to determine whether STAT1 function 
was necessary for the ability of gp130-induced signaling to inhibit adipocyte 
differentiation. To accomplish this goal, we adopted a shRNA knockdown strategy using 
STAT1-specific shRNAs to stably deplete endogenous STAT1 levels in 3T3-L1 
preadipocytes. By initially screening a panel of STAT1-specific shRNAs we were able to  
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FIGURE 11. STAT1-depletion rescues adipocyte differentiation from the 
EpoR/gp130-chimeric receptor signaling.  
 
 
(A) 3T3-L1 preadipocyte cells transduced with retroviruses encoding either a control 
shRNA or one of two independent STAT1-specific shRNAs (924 & 927), were super-
infected with a MSCV-EG-WT encoding retrovirus and whole cell extracts from these 
cells were analyzed by immunoblotting with antibodies specific for STAT1, EpoR and 
 
74 
 
 
STAT3 as a protein loading control and to show specificity of the shRNA knockdown. 
(B, C) These independent cell populations were then induced to differentiate with MDI in 
the presence of Epo for the initial 48 h and after 8 days, the extent of adipocyte 
differentiation was assessed by ORO staining (B) and immunoblotting for the expression 
of PPARγ and aP2 (C). Results are representative of two independent experiments. 
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FIGURE 12. STAT1-depletion rescues adipocyte differentiation from the IL-11 
cytokine.  
 
 
3T3-L1 preadipocyte cells transduced with either control shRNA or STAT1-specific 
shRNA (924 & 927) encoding retroviruses were induced to differentiate with MDI in the 
presence of IL-11 for the initial 48 h and the extent of adipocyte differentiation was 
assessed at day 8 by either ORO staining (A) or immunoblotting for the expression of 
PPARγ and aP2 (B). Results are representative of two independent experiments. 
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identify two independent shRNAs capable of efficiently and specifically depleting 
endogenous levels of STAT1 (Fig. 11A). 3T3-L1 preadipocytes expressing either of these 
two independent STAT1-specific shRNAs or a control shRNA were then each 
superinfected with a retrovirus encoding EG-WT and induced to undergo adipocyte 
differentiation in the presence of Epo. As expected, when control shRNA expressing cells 
were treated with Epo their differentiation was potently inhibited (Fig. 11B, C). In 
contrast, we found that the inhibitory effect of Epo was greatly attenuated in cells 
expressing either of the two STAT1-specific shRNAs (Fig. 11B, C). Similarly, we found 
that these two STAT1-specific shRNAs also greatly attenuated the ability of exogenous 
IL-11 to inhibit adipocyte differentiation (Fig. 12 A, B). It is noteworthy that in each case 
the degree of rescue caused by each of the STAT1-specific shRNAs was proportional to 
their degree of knockdown of endogenous STAT1 levels. 
Next, we wished to examine the requirement for STAT1 as a downstream anti-
adipogenic effector of the PGF2α/calcineurin-signaling pathway. As shown in Fig. 13A, 
B, while PGF2α effectively inhibited the differentiation of control shRNA-expressing 
cells as expected, we found that depletion of endogenous STAT1 levels with either of our 
STAT1-specific shRNAs allowed for significant rescue of adipogenesis in the presence 
of inhibitory concentrations of PGF2α capable of potently inhibiting control cells. Taken 
together, these data identify an important role for STAT1 as a critical downstream 
effector in mediating the inhibitory effects of PGF2α and IL-11/gp130-signaling on 
adipocyte differentiation. 
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FIGURE 13. STAT1-depletion rescues adipocyte differentiation from PGF2α.  
3T3-L1 preadipocyte cells transduced with either control shRNA or STAT1-specific 
shRNA (924 & 927) encoding retroviruses were induced to differentiate with MDI in the 
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presence of increasing concentrations of PGF2α for the initial 48 h and the extent of 
adipocyte differentiation was assessed after 8 days by ORO staining (A) and 
immunoblotting for the expression of PPARγ and aP2 (B). Results are representative of at 
least five independent experiments. 
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5.6 STAT1 depletion enhances the efficiency of adipocyte differentiation: Evidence 
for an intrinsic negative regulatory role: In addition to the well-known anti-adipogenic 
effects of exogenous PGF2α, prior studies have revealed that PGF2α also serves as an 
important endogenous negative regulator of adipogenesis that is naturally synthesized 
transiently by preadipocytes early during the normal differentiation process, and acts in 
an autocrine-mediated, negative feedback loop to restrict the overall adipogenic capacity 
of these cells (Fujimori et al., 2010a; Fujimori et al., 2010b; Silvestri et al., 2013). This 
led us to hypothesize that this endogenous PGF2α-mediated negative feedback pathway 
is also likely to involve the calcineurin/IL-11/gp130/STAT1 signaling axis that we have 
described above. Consistent with this notion we find that 3T3-L1 preadipocyte cells 
induced to differentiate by the standard MDI-induced adipogenic protocol transiently 
secrete low levels of IL-11 early during the differentiation process, peaking at 24 hrs 
post-induction and falling to background levels by 48 hrs (Fig. 14A). Moreover, we find 
that this increase in IL-11 secretion is inhibited in the presence of CsA, indicating that it 
is dependent upon the activation of calcineurin, which is presumably induced in response 
to endogenously produced PGF2α. It is noteworthy, however, that the level of IL-11 
secretion detected here during normal adipocyte differentiation is considerably less than 
that induced in response to exogenous PGF2α (0.278 pg/ml versus 11.6 ng/ml).  
Having demonstrated that IL-11 is naturally produced during the normal process 
of adipocyte differentiation, we next sought to determine whether the IL-
11/gp130/STAT1 signaling axis served as an intrinsic negative regulator of the adipocyte 
differentiation pathway designed to restrict the adipogenic potential of preadipocyte cells.  
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FIGURE 14. STAT1-depletion enhances the efficiency of adipocyte differentiation in 
response to suboptimal adipogenic stimulation.  
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(A) 3T3-L1 cells were induced to differentiate by the standard MDI-induced protocol in 
the presence and absence of CsA and culture supernatants were assayed after 24 h for the 
presence of IL-11 by ELISA, (B, C) 3T3-L1 preadipocyte cells transduced with either 
control shRNA or STAT1-specific shRNA (924) encoding retroviruses were exposed to a 
suboptimal adipogenic cocktail comprising of decreasing serial dilutions of MD alone in 
the absence of exogenously added insulin. After 8 days, the extent of adipocyte 
differentiation was assessed by ORO staining (B) and immunoblotting for the expression 
of PPARγ and aP2 (C). The extent of STAT1 depletion was confirmed by 
immunoblotting for STAT1, while immunoblot analysis of STAT3 served as a control for 
knockdown specificity and equal protein loading. The data is shown as mean ± SEM 
(Student’s t test; p<0.05; n=3). ND; not detectable. Results are representative of three 
independent experiments. 
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We reasoned that if this were the case, then inhibition of this pathway should enhance the 
efficiency of the differentiation process. For these experiments we took advantage of the 
observation that treatment of 3T3-L1 preadipocytes with suboptimal adipogenic stimuli 
(reduced concentrations of Mix and Dex in the absence of insulin) results in barely 
detectable levels of adipocyte differentiation (Fig. 14B, C). However, in contrast, we find 
that when the integrity of the IL-11/gp130/STAT1 signaling pathway is abrogated by 
depletion of endogenous STAT1 proteins, a significant degree of adipocyte 
differentiation is observed in response to these suboptimal doses of adipogenic stimuli 
(Fig 14B, C). In fact, we find that even in the presence of optimal doses of adipogenic 
stimuli, we consistently observe enhanced levels of adipocyte differentiation (as indicated 
by increased ORO staining and expression of the adipogenic marker proteins, PPARγ and 
aP2), in cells in which the IL-11/gp130/STAT1 signaling axis has been inhibited, either 
as a result of STAT1 knockdown or via ectopic expression of DN-gp130 (see Fig. 5 and 
13). Hence, these results strongly suggest that the IL-11/gp130/STAT1 signaling pathway 
does indeed represent an intrinsic negative regulatory pathway that serves to restrict the 
adipogenic potential of preadipocyte cells.  
 
6. DISCUSSION 
Recent studies identifying an emerging in vivo role for PGF2α as an important 
endogenous negative regulator of adipocyte differentiation involved in opposing the 
development of obesity and its contingent pathological metabolic sequelae (Volat et al., 
2012), have raised considerable interest in elucidating the molecular pathways and 
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mechanisms by which this important prostaglandin mediates its inhibitory effects on 
adipogenesis. Building upon our previous identification of calcineurin as a critical 
downstream anti-adipogeneic effector of PGF2α (Liu and Clipstone, 2007), we have now 
further delineated the molecular mechanism by which this signaling pathway inhibits 
adipocyte differentiation. Collectively, our findings support a model in which exposure of 
differentiating 3T3-L1 preadipocytes to PGF2α results in the initial calcineurin-
dependent expression and secretion of the IL-11 cytokine, which then acts in an 
autocrine/paracrine fashion to inhibit adipocyte differentiation via the essential actions of 
the gp130 cytokine co-receptor signaling subunit and the subsequent activation of the 
STAT1 transcription factor. 
Our results clearly identify IL-11 as a downstream transcriptional target of the 
PGF2α/calcineurin-signaling pathway in 3T3-L1 preadipocytes. Interestingly, this same 
pathway has also recently been shown to induce IL-11 expression in endometrial 
adenocarcinoma cells via the calcineurin-dependent activation of the nuclear factor of 
activated T cells (NFAT) transcription factor family (Sales et al., 2010). By analogy with 
this finding, together with the knowledge that NFAT proteins are expressed in 3T3-L1 
preadipocytes (Ho et al., 1998), it is tempting to speculate that NFAT proteins are also 
likely to play a role in coupling the PGF2α/calcineurin-signaling pathway to the 
expression of IL-11 in these cells. However, the recent demonstration that IL-11 can be 
transcriptionally regulated by the hypoxia-inducible  factor 1 transcription factor (Onnis 
et al., 2013), which we have previously shown is activated in 3T3-L1 cells in response to 
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PGF2α stimulation (Liu and Clipstone, 2008), raises the possibility that this pathway 
may also play a role. 
IL-11 has long been known to be a potent inhibitor of adipocyte differentiation 
(Kawashima et al., 1991; Keller et al., 1993). Moreover, 3T3-L1 preadipocytes are 
known to express functional IL-11 receptors (Tenney et al., 2005). Hence, our 
observation that activation of the PGF2α/calcineurin-signaling pathway in 3T3-L1 
preadipocytes induces the expression and subsequent secretion of IL-11, strongly 
suggested a model in which PGF2α inhibits adipocyte differentiation by means of an 
autocrine IL-11-mediated negative regulatory pathway. Evidence in support of this model 
is provided by our dual observation that both the shRNA-mediated knockdown of IL-11 
and the dominant-negative inhibition of the gp130 cytokine co-receptor signaling subunit, 
an essential signaling component of the IL-11 receptor, are both able to rescue 3T3-L1 
preadipocyte differentiation in the presence of inhibitory concentrations of PGF2α. 
Together, these results demonstrate that the ability of PGF2α to inhibit adipocyte 
differentiation is dependent upon both IL-11 and gp130 cytokine co-receptor signaling. In 
this regard, although the DN-gp130 mutant used in our experiments is capable of 
inhibiting IL-11 signaling, it can also inhibit signaling via all other members of the IL-6 
cytokine family, whose receptors all share the same gp130 cytokine co-receptor signaling 
subunit (Heinrich et al., 2003; Taga and Kishimoto, 1997). However, of this family of 
cytokines, we find that only IL-11 and, to a somewhat lesser extent, IL-6 (Fig.4), is 
significantly induced by the PGF2α/calcineurin-signaling pathway in differentiating 3T3-
L1 preadipocytes. Hence, based upon our collective data, we conclude that IL-11, acting 
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in an autocrine fashion via a critical gp130 cytokine co-receptor-dependent mechanism, 
most likely plays the prominent role in mediating the inhibitory effects of the 
PGF2α/calcineurin-signaling pathway on adipocyte differentiation, although we do not 
rule out the possibility that IL-6, and potentially other related family members, may also 
additionally contribute. 
Having identified a clear role for the gp130-signaling axis in mediating the 
inhibitory effects of the PGF2α/calcineurin-signaling pathway on adipocyte 
differentiation, and having further showed that the activation of gp130-dependent 
signaling per se is sufficient to inhibit the adipogenic process, our attention naturally 
focused towards investigating the underlying gp130-dependent mechanisms involved. In 
this respect, signaling via the gp130 cytokine co-receptor signaling subunit has been 
extensively characterized and is known to primarily involve the activation of both the 
STAT1 and STAT3 latent transcription factors and the MAPK signaling pathway 
(Heinrich et al., 2003). By turning to previously characterized chimeric mutants of gp130 
known to be selectively deficient in the activation of either one of these latter pathways 
(Schaper et al., 1998; Schmitz et al., 2000), we were able to interrogate their respective 
roles in mediating the inhibitory effects of gp130 signaling on adipogenesis. Surprisingly, 
although the MAPK signaling pathway has previously been shown to inhibit adipocyte 
differentiation in certain contexts (Font de Mora et al., 1997; Tanabe et al., 2004), we 
found that tyrosine 759, responsible for coupling gp130 to the activation of MAPK, was 
completely dispensable for the inhibitory effects of gp130 signaling. Conversely, we 
found that the ability of gp130 to inhibit adipocyte differentiation was critically 
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dependent upon the conserved tyrosine residues known to be involved in the activation of 
STAT1 and STAT3, suggesting a potentially important role for STAT transcription 
factors. By adopting the use of additional gp130 mutant receptors that are preferentially 
able to activate either STAT1 or STAT3 (Gerhartz et al., 1996), we were able to 
demonstrate that the gp130-mediated inhibition of adipogenesis correlated most closely 
with the activation of STAT1, but not STAT3. More significantly, we found that the 
shRNA-mediated depletion of endogenous STAT1 protein served to largely attenuate the 
inhibitory effects of either IL-11 or chimeric EpoR/gp130 receptor signaling on 3T3-L1 
preadipocyte differentiation, as well as significantly rescue adipogenesis in the presence 
of PGF2α. Taken together, therefore, our data provides evidence that STAT1 plays an 
important role in mediating the inhibitory effects of the PGF2α/calcineurin-signaling 
pathway on adipogenesis, where it appears to serve as a critical negative regulatory 
effector downstream of gp130 receptor complexes to couple PGF2α/calcineurin-induced 
autocrine IL-11 cytokine signaling-events to the inhibition of adipocyte differentiation 
(see Fig. 15). 
Our identification of STAT1 as a negative regulator of adipocyte differentiation is 
consistent with prior studies that have suggested a potential role for STAT1 in mediating 
the anti-adipogenic effects of IFNγ (McGillicuddy et al., 2009; Waite et al., 2001). 
Interestingly, in contrast to the anti-adipogenic role of STAT1, other members of the 
STAT transcription factor family, namely STAT3 and STAT5 (Richard and Stephens, 
2011), have conversely been reported to play pro-adipogenic roles. In this regard, STAT3 
has been proposed to play a role in promoting the expression of the early transcription 
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factor C/EBPβ and is believed to play a critical role in the mitotic clonal expansion phase 
of adipogenesis (Deng et al., 2000; Zhang et al., 2011), whereas STAT5 has been 
reported to make a more direct contribution towards adipocyte differentiation by directly 
helping promote the expression of PPARγ (Kawai et al., 2007; Nanbu-Wakao et al., 
2002). STAT proteins therefore play complex, diverse and opposing roles in the 
regulation of adipocyte differentiation. By virtue of their established regulatory roles and 
specific activation in response to diverse ligand-activated plasma membrane receptors 
(Levy and Darnell, 2002; Levy and Darnell, 2002), STAT proteins offer the opportunity 
to modulate and fine-tune the efficiency of the adipogenic process in response to 
changing extracellular cues. However, exactly how the relative activities of these related 
transcription factors are integrated at the level of the transcriptome to influence the 
adipogenic cell fate decision remains to be determined. 
Mechanistically, it is currently unclear how STAT1 activation results in the 
inhibition of adipocyte differentiation. However, we believe that STAT1 likely acts at a 
point proximal to the expression of the PPARγ master adipogenic transcription factor, as 
our data shows that gp130 signaling is sufficient to attenuate the expression of PPARγ in 
a STAT1-dependent manner, whereas ectopic expression of PPARγ2 is able to readily 
bypass the inhibitory effects of gp130-mediated signaling (see Fig. 8). While STAT1 is 
commonly thought to primarily play a role as a positively acting transcription factor, it is 
evident that it can also act to inhibit transcriptional events in certain biological contexts 
(Furukawa et al., 2009; Liu et al., 2008; Ramana et al., 2000). Hence, we envision that 
STAT1 may contribute towards the inhibition of adipocyte differentiation via either of 
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two non-mutually exclusive mechanisms. On the one hand, the most direct mechanism by 
which STAT1 may inhibit adipogenesis is via the direct repression of a critical pro-
adipogenic gene(s) that is required for adipogenesis. In this regard, it is perhaps 
noteworthy that a nucleotide region capable of specifically binding STAT1 in vitro has 
previously been identified in the immediate upstream regulatory region of the murine 
PPARγ2 promoter and has been proposed to play a negative regulatory role in the 
expression of this critical pro-adipogenic transcription factor (Hogan and Stephens, 
2001), thereby raising the possibility that STAT1 may inhibit adipogenesis by directly 
blocking the expression of PPARγ itself. Alternatively, STAT1 may contribute to the 
inhibition of adipocyte differentiation via a more indirect mechanism in which STAT1 is 
responsible for inducing the expression of a distinct anti-adipogenic gene(s) that is in turn 
itself responsible for inhibiting the adipogenic process. In this respect, the increased 
expression of many genes and microRNAs are known to be capable of inhibiting 
adipogenesis by preventing expression of PPARγ (McGregor and Choi, 2011; Rosen and 
MacDougald, 2006), although whether any of these known inhibitors act as functional 
downstream anti-adipogenic effectors of STAT1 remains to be determined. 
Consequently, the respective roles of either of these two non-mutually exclusive 
pathways in mediating the STAT1-dependent inhibition of adipocyte differentiation and 
the precise molecular mechanism(s) involved await further investigation. 
Finally, while PGF2α has long been known to be a potent exogenous inhibitor of 
adipocyte differentiation in vitro (Casimir et al., 1996; Lepak and Serrero, 1993; Liu and 
Clipstone, 2007; Miller et al., 1996; Serrero et al., 1992), more recent data has  
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FIGURE 15. Schematic model illustrating the proposed mechanism by which PGF2α 
inhibits adipogenesis.  
 
 
The PGF2α/calcineurin-signaling pathway induces IL-11 expression, which in turn binds 
to the non-signaling IL-11Rα receptor subunit, recruits the gp130 co-receptor signaling 
subunit and then, activates STAT1 transcription factor. It is the activation of STAT1 
transcription factor that mediates the inhibitory effects of PGF2α on adipogenesis. 
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highlighted an emerging in vivo role for PGF2α as an important endogenous negative 
regulator of adipogenesis that is naturally synthesized by preadipocytes early during the 
normal differentiation process, and appears to participate in an autocrine-mediated, 
negative feedback loop that acts to restrict the overall adipogenic capacity of these cells 
(Fujimori et al., 2010a; Fujimori et al., 2010b; Silvestri et al., 2013).We believe that this 
latter negative feedback loop likely proceeds, at least in part, via the calcineurin/IL-
11/gp130/STAT1-mediated pathway that we have described here. In support of this 
notion, we find that low levels of IL-11 are secreted in a calcineurin-dependent fashion 
during the normal MDI-induced differentiation of 3T3-L1 preadipocytes, presumably in 
response to the autocrine action of elevated levels of endogenously produced PGF2α. 
Furthermore, we find that inhibition of the endogenous calcineurin/IL-11/gp130/STAT1 
signaling pathway results in enhanced differentiation of 3T3-L1 preadipocytes, especially 
under conditions of suboptimal adipogenic stimulation (Fig. 5 and Fig. 14). These results 
therefore argue that this pathway represents an intrinsic negative regulatory feedback 
mechanism that serves to restrict the differentiation of preadipocyte cells and thereby 
plays a major role in determining the efficiency of the adipogenic process. Given the fact 
that adipocyte-derived PGF2α production has been implicated as an important negative 
regulator of adipose tissue expansion in vivo, involved in opposing the development of 
obesity and its attendant diseases (Volat et al., 2012), it is tempting to speculate that these 
effects, at least in part, are also mediated by this same calcineurin/IL-11/gp130/STAT1-
signaling module. 
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CHAPTER IV 
THE PGF2α/CALCINEURIN-SIGNALING PATHWAY UPREGULATES        
THE EXPRESSION OF THE ORPHAN NUCLEAR HORMONE RECEPTOR 
NURR1 THROUGH A CRTC/CREB-DEPENDENT MECHANISM:                           
A POTENTIAL ROLE IN INHIBITING ADIPOCYTE DIFFERENTIATION
 
 
1. Introduction: In addition to the increased expression of the IL-11 cytokine 
documented in the previous chapter, our microarray analysis revealed that the 
PGF2α/calcineurin-signaling pathway also highly induced the expression of an orphan 
nuclear hormone receptor, Nurr1 which is a member of the NR4A family of nuclear 
hormone receptors which also includes Nur77 and Nor1. This was of interest as the 
members of this family had previously been implicated in the negative regulation of 
adipocyte differentiation. However, the role of Nurr1 in the PGF2α-mediated inhibition 
of adipogenesis had not previously been investigated. 
 
2. Nurr1 and its family members (NR4A Family):  
2.1 Expression and functions of NR4A family members: Nurr1 and its related family 
members are considered to be immediate early genes and are rapidly induced by a wide 
variety of physiological stimuli, including cAMP, phorbol esters, prostaglandins, 
calcium, fatty acids, stress and growth factors (Maxwell and Muscat, 2006; Pearen and 
Muscat, 2010). They are expressed in multiple tissues including adipose tissue, skeletal 
muscle, kidney, heart, T-cells, macrophages, liver and brain 
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(Maxwell and Muscat, 2006; Pearen and Muscat, 2010). They are known to play a 
diverse role in the regulation of cellular and physiological functions including a critical 
role in metabolism, inflammation and vascular remodeling (McMorrow and Murphy, 
2011; Zhao and Bruemmer, 2010). Importantly, Nurr1 is critical for the development of 
dopaminergic neurons (Zetterstrom et al., 1997) and mutations in Nurr1 have been linked 
to the development of Parkinson’s disease (Le et al., 2003; Sirin et al., 2010). Nurr1 has 
also been shown to inhibit the proliferation of haematopoietic stem cells (Sirin et al., 
2010). 
 
2.2 Role of Nurr1 and its family members in adipogenesis: While these receptors are 
expressed at very low to undetectable levels in undifferentiated 3T3-L1 preadipocytes, 
they are rapidly and transiently induced by MDI stimulation, reaching a peak level within 
the first 4 h of the differentiation process, which then decreases to the basal level within 
16 to 24 h (Fu et al., 2005; Soukas et al., 2001). Despite their rapid expression after 
adipogenic stimulation, their exact role in normal adipogenic process is not known. 
However, the over expression of Nurr1 and its family members are shown to inhibit 
adipocyte differentiation (Chao et al., 2008). Conversely, Au et al (2008) suggested that 
NR4A receptors are not required for adipogenesis, as the expression of a well 
characterized-dominant-negative Nur77 that is known to block the function of all three 
members Nur77, Nurr1 and Nor1 did not block adipogenesis (Au et al., 2008). While we 
find that Nurr1 is highly induced by PGF2α during adipogenesis, its exact role in 
mediating the inhibitory effects of PGF2α on adipogenesis is not known. 
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2.3 Structure and regulation of Nurr1 activity: Like other nuclear hormone receptors, 
NR4A family members contain a highly conserved central DNA binding domain, an N-
terminal ligand-independent, AF-1 transactivation domain and a C-terminal ligand-
binding, AF-2 transactivation domain (Maruyama et al., 1998). In contrast to other 
nuclear hormone receptors, the crystal structure of Nurr1 shows that its ligand-binding 
pocket is filled with bulky hydrophobic side chains and thus, it cannot be regulated by a 
ligand (Flaig et al., 2005; Wang et al., 2003). In fact, the crystal structures show that 
Nurr1 assumes the conformation of an active receptor even in the absence of a ligand 
(Wang et al., 2003). Considering this observation, it seems that Nurr1 functions as a 
constitutively active, ligand-independent receptor and its activity is primarily dependent 
on its expression and posttranslational modifications. In fact, the mitogen-activated 
protein kinase (ERK1, 2/ERK5) has been shown to positively regulate the transcriptional 
activity of Nurr1 via phosphorylation of specific amino acids in the N-terminal AF-1 
region, whereas LIM kinase 1 has been shown to negatively regulate Nurr1 
transcriptional activity (Sacchetti et al., 2006). In addition, Nurr1 protein level has been 
shown to be regulated by the ubiquitin-proteasome pathway via its N-terminal region. 
Thus, the transcriptional activity of Nurr1 is regulated by multiple mechanisms (Alvarez-
Castelao et al., 2013). 
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FIGURE 16. Schematic model showing the structure of Nurr1 and the modes of 
regulation of gene expression by Nurr1.  
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(A) Nurr1 contains an N-terminal AF-1 domain, a central DNA binding domain and a C-
terminal AF-2 domain. (B-D) Nurr1 directly binds to DNA and regulates gene expression 
as either monomer, homodimer or as a heterodimer with RxR. (E) Nurr1 indirectly 
inhibits gene expression through interacting with the DNA bound NF-κB and recruitment 
of co-repressor, CoREST. 
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2.4 Regulation of gene expression by Nurr1 and its family members: NR4A family 
members regulate gene expression as either monomers or homodimers by binding to 
canonical DNA binding site called the nerve growth factor-induced protein B-responsive 
element (NBRE) (Fig. 16B, C) (Maira et al., 1999; Paulsen et al., 1995; Philips et al., 
1997). Further, Nurr1 and Nur77 also heterodimerize with the retinoid X receptor (RXR) 
and induce gene transcription by binding to DNA response elements composed of direct 
repeats of consensus nuclear hormone response elements spaced by five nucleotides 
called DR5 (Fig. 16D) (Perlmann and Jansson, 1995; Zetterstrom et al., 1997). While 
Nurr1 has previously been shown to act as a positive transcription factor by inducing 
gene expression via direct DNA binding to promoter regions (Davies et al., 2005; Lammi 
et al., 2004; Sakurada et al., 1999), it is also clear that Nurr1 is able to repress the 
expression of certain other genes (Kim et al., 2013; Kim et al., 2013; Mix et al., 2007; 
Wu et al., 2005). In addition, the effects of Nurr1 do not always require it to directly bind 
to DNA, as recent studies have indicated that Nurr1 can repress transcription of certain 
genes indirectly by forming a complex with DNA-bound NF-κB and recruitment of 
CoREST co-repressor complex (Fig. 16E) (Saijo et al., 2009). 
 
2.5 Regulation of Nurr1 expression by the calcineurin phosphatase and the 
CRTC2/CREB transcriptional complex: The Nurr1 promoter contains a consensus 
cAMP response element (CRE) and has been shown to be regulated by the CREB 
transcription factor in multiple cell types (Ji et al., 2012; McEvoy et al., 2002; Zhao et al., 
2011). Interestingly, CREB-induced Nurr1 expression is selectively regulated by the 
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CRTC2 co-activator (Conkright et al., 2003). More importantly, CRTC2 is activated by a 
cAMP and calcineurin-dependent mechanism (Screaton et al., 2004), as described later in 
this chapter and Nurr1 expression is widely used as a marker to determine the activation 
and the transcriptional regulation of CRTC2 (Conkright et al., 2003). In addition, a recent 
study using hippocampal neurons shows that Nurr1 expression is regulated by an increase 
in intracellular calcium through voltage-gated calcium channel and subsequent activation 
of the calcium-dependent phosphatase, calcineurin (Tokuoka et al., 2014). Thus, 
calcineurin appears to play a crucial role in the upregulation of Nurr1 expression in 
multiple cell types. 
 
3. CREB transcription factor: CREB belongs to the basic leucine zipper (bZIP) family 
of transcription factors and is ubiquitously expressed in multiple tissues (Carlezon et al., 
2005; Shaywitz and Greenberg, 1999). It is activated by a diverse array of extracellular 
stimuli including peptide hormones, growth factors, osmotic stress, ultraviolet irradiation 
and neuronal activity (Carlezon et al., 2005; Shaywitz and Greenberg, 1999). The 
transcriptional activity of CREB is regulated by the phosphorylation of serine 133 by 
different serine-threonine kinases including cAMP-dependent protein kinase A (PKA), 
protein kinase C (PKC), calmodulin kinases (CaMKs) and ribosomal S6 kinase 
(Gonzalez and Montminy, 1989; Gubina et al., 2001; Seamon et al., 1981; Sheng et al., 
1991; Xing et al., 1996). Once CREB is phosphorylated on serine 133, it dimerizes, binds 
to its co-activators, CREB-binding protein (CBP) or p300 (Arias et al., 1994; Chrivia et 
al., 1993; Kwok et al., 1994) and, then induces the expression of its target genes through 
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binding to CREB-responsive element (CRE), which consist of either palindromic (5’-
TGACGTCA-3’) or half-site (TGACG or CGTCA) sequences (Comb et al., 1986; 
Montminy et al., 1986).  
CREB plays a diverse role in the regulation of various physiological and 
pathological process including cell differentiation, glucose and lipid metabolism in liver, 
immune function, cell survival in neurons and pancreatic β-cells, consolidation of 
memory, cancer progression and others (Carlezon et al., 2005; Herzig et al., 2001; Herzig 
et al., 2003; Hong et al., 2005; Pittenger et al., 2002; Wen et al., 2010). More importantly, 
CREB is constitutively expressed in preadipocytes (Reusch et al., 2000) and plays 
multiple roles during adipocyte differentiation by regulating the expression of several 
genes involved in adipogenesis, which is discussed in the chapter I of this dissertation. 
 
4. CRTC family of transcriptional co-activators: The CRTC proteins are a family of 
recently identified co-activators of the CREB transcription factor and consist of three 
members: CRTC1, CRTC2 and CRTC3 (Conkright et al., 2003; Iourgenko et al., 2003). 
CRTC1 is highly expressed in brain, whereas CRTC2 and CRTC3 are abundantly 
expressed in multiple tissues (Conkright et al., 2003). Under basal conditions, CRTCs are 
highly phosphorylated and retained in the cytoplasm by interactions with 14-3-3 adaptor 
protein (Screaton et al., 2004). Specifically, CRTC2 is highly phosphorylated at serine 
171 and 275 by salt inducible kinase (SIK1) and MARK1, respectively (Screaton et al., 
2004). The phosphorylation of these residues form docking site for 14-3-3 adaptor 
proteins, thereby CRTC2 is retained in the cytoplasm in an inactive form. However, when  
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FIGURE 17. Schematic model showing the activation of the CRTC2 co-activator.  
 
Under basal conditions, CRTC2 is highly phosphorylated and retained in the cytoplasm 
by the 14-3-3 adaptor protein. Upon stimulation with appropriate stimuli, CRTC2 is 
dephosphorylated by a cAMP and calcineurin-dependent mechanism and subsequently, 
translocates into the nucleus, where it interacts with CREB and enhances the 
transcriptional activity of the CREB. 
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the cells are stimulated with appropriate stimuli, SIK1 is inactivated by PKA-dependent 
inhibitory phosphorylation, whereas calcineurin dephosphorylates serine 275 (Screaton et 
al., 2004). The dephosphorylation of CRTC2 by these two mechanisms releases it from 
14-3-3 adaptor proteins, resulting in the translocation of CRTC2 to nucleus where it binds 
to the bZIP domain of CREB and promote the transcriptional activity of CREB (Fig. 17) 
(Screaton et al., 2004). In fact, CRTCs do not modulate the DNA binding ability of 
CREB, but rather enhance the transcriptional activity of CREB by augmenting it’s 
interaction with the TAFII130 component of transcription factor II D (TFIID) (Conkright 
et al., 2003). More importantly, CRTCs regulate the transcriptional activity of CREB in a 
canonical serine 133 phosphorylation-independent mechanism. The activity of CRTC2 is 
terminated by the prolyl-isomerase Pin1, which interacts with serine 136 in the nuclear 
localization signal of CRTC2 and promotes its export from the nucleus to cytosol 
(Nakatsu et al., 2010). 
CRTCs are known to regulate a variety of biological processes. CRTC1 regulates 
satiety, circadian clock, snaptic plasticity and memory in the brain (Sakamoto et al., 
2013; Sekeres et al., 2012; Zhou et al., 2006), whereas CRTC2 and CRTC3 are primarily 
involved in the regulation of metabolism in the liver and adipose tissue (Dentin et al., 
2007; Song et al., 2010; Wang et al., 2012). In the liver, CRTC2 is highly phosphorylated 
in response to insulin, resulting in its nuclear exclusion and degradation (Dentin et al., 
2007), whereas glucagon causes dephosphorylation and nuclear translocation of CRTC2, 
resulting in the expression of gluconeogenic genes (Wang et al., 2012). CRTC3 has been 
shown to attenuate the β-adrenergic receptor signaling in adipose tissue by upregulating 
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the expression of regulator of G-protein signaling 2 (Rgs2) (Song et al., 2010). While the 
CRTC proteins are shown to play a diverse role in multiple tissues, their role in adipocyte 
differentiation is not known.  
In this chapter, we investigated the molecular mechanism by which the 
PGF2α/calcineurin-signaling pathway induces Nurr1 expression during adipocyte 
differentiation and the functional significance of increased Nurr1 expression in mediating 
the inhibitory effect on adipogenesis. First, we show that PGF2α upregulates the 
expression Nurr1 in a calcineurin-dependent fashion. Next, we show that the expression 
of a dominant-negative Nurr1 partially rescues adipogenesis from the inhibitory effects of 
PGF2α. Then, using a panel of Nurr1 mutants, we demonstrate that the direct DNA 
binding of Nurr1, but not its heterodimerization with RxR is required to inhibit 
adipogenesis. In addition, using a panel of CREB mutants and the shRNA approach, we 
demonstrate that PGF2α-mediated activation of the CRTC/CREB transcriptional complex 
induces Nurr1 expression. Collectively, these results demonstrate that the 
PGF2α/calcineurin-signaling pathway inhibits adipogenesis by inducing the expression of 
Nurr1 through activation of the CRTC/CREB-transcriptional complex. 
 
5. RESULTS 
 
5.1 The PGF2α/calcineurin-signaling pathway induces Nurr1 expression in 
differentiating 3T3-L1 preadipocytes: Our previous studies showed that PGF2α 
inhibits adipocyte differentiation through a calcium-dependent phosphatase calcineurin 
(Liu and Clipstone, 2007), which is well-known to regulate gene expression through  
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FIGURE 18. The PGF2α/calcineurin-signaling pathway induces Nurr1 expression, 
but not other family members during adipocyte differentiation.  
 
 
Two-day post confluent 3T3-L1 preadipocytes were induced to undergo adipocyte 
differentiation by treatment with MDI in the presence of either vehicle, PGF2α (25 nM) 
alone or PGF2α (25 nM) plus cyclosporine A (CsA) (1 µg/ml). At 48 h post-stimulation, 
total RNA and total cell lysates were collected. (A) The expression of Nurr1 and Nur77 
was determined by qRT-PCR and (B) Nurr1 expression was determined by 
immunoblotting. The data is shown as mean ± SEM (one-way ANOVA followed by 
Bonferroni post hoc test; p<0.05; n=3). Results are representative of at least three 
independent experiments.  
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activation of various transcriptional regulators. As previously discussed, we performed an 
initial microarray experiment to identify the potential downstream effectors of the 
PGF2α/calcineurin-signaling pathway during adipogenesis. In addition to the IL-11 
cytokine discussed in the chapter III, our analysis also identified an orphan nuclear 
hormone receptor, Nurr1 as one of the most highly induced genes by the 
PGF2α/calcineurin-signaling pathway during adipogenesis. This was of interest, as Nurr1 
and its family members are known to play a role in the regulation of cell differentiation 
and development, and their over expression has previously been shown to inhibit 
adipocyte differentiation (Chao et al., 2008). 
 To confirm the initial microarray data, 3T3-L1 cells were induced to differentiate 
with the MDI-induced differentiation protocol in the presence or absence of PGF2α or 
pretreatment with the calcineurin inhibitor, CsA. At 48 h post-induction, mRNA and 
protein were collected for qRT-PCR and immunoblotting, respectively. During 
adipogenesis, Nurr1 expression was undetectable with MDI alone, whereas PGF2α 
significantly induced Nurr1 expression at both the mRNA and protein level at 48 h post-
stimulation (Fig. 18A, B). Importantly, the PGF2α-induced Nurr1 expression was 
attenuated to the basal level with CsA pretreatment, which indicates a role of calcineurin 
in mediating the PGF2α-induced Nurr1 expression during adipogenesis. Interestingly, 
another family member Nur77 was not significantly induced by PGF2α and Nor1 was 
undetectable with four different primer pairs. Collectively, these results demonstrate that 
PGF2α selectively upregulates Nurr1 expression through the activation of the calcineurin 
phosphatase. 
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5.2 Nurr1 plays a potential role in mediating the inhibitory effects of PGF2α on 
adipocyte differentiation: Having shown that PGF2α induces Nurr1 expression during 
adipogenesis, we next determined whether Nurr1 is necessary for PGF2α to inhibit 
adipocyte differentiation. To accomplish this, we initially tried to stably knockdown the 
expression of Nurr1 in 3T3-L1 cells using shRNA approach. However, our attempts to 
deplete the expression of Nurr1 by several shRNAs were unsuccessful. Hence, we took 
advantage of a dominant-negative mutant that is known to inhibit the activity of all three 
members of NR4A2 family of orphan nuclear receptors. This dominant-negative mutant 
contains the DNA binding domain of Nurr1 fused with the transcriptional repressor 
domain of the KRAB repressor (DN-Nurr1; Fig. 19A). First, we determined whether this 
DN-Nurr1 is functional by transient transfection luciferase reporter gene assay in 
HEK293T cells. As described in the materials and methods, we transfected these cells 
with equal concentrations of plasmid encoding wild-type Nurr1 (Nurr1-WT) and 
increasing concentrations of DN-Nurr1 plasmids. Simultaneously, the cells were also 
transfected with the Nurr1 reporter, (NBRE)3-TK-LUC and pRG-TK reporter plasmids. 
At 24 h post-transfection, cell lysates were prepared and the luciferase bioluminescence 
was determined. As shown in Figure 19B, Nurr1-WT expression showed a maximal 
luciferase activity, whereas there was a dose-dependent inhibition of Nurr1-WT activity 
by DN-Nurr1 as measured by the luciferase activity. This demonstrates that the DN-
Nurr1 is functional and it inhibits the transcriptional activity of the wild-type Nurr1.  
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FIGURE 19. Evidence that Nurr1 potentially plays a role in mediating the inhibitory 
effects of PGF2α on adipogenesis.  
 
 
(A) Schematic model illustrating the dominant-negative Nurr1 (DN-Nurr1). (B) 
HEK293T cells were transfected with Nurr1-WT (100 ng) and increasing concentrations 
of DN-Nurr1 (0, 100, 200 and 400 ng) along with (NBRE)3-TK-Luc (50 ng) and pRG-
TK (25 ng) reporter plasmids. At 24 h post-transfection, luciferase assay was performed 
and the percent maximal luciferase activity was calculated. (C, D) 3T3-L1 preadipocytes 
transduced with either MSCV-GFP or DN-Nurr1 encoding retroviruses were induced to 
differentiate with MDI in the presence of the indicated concentrations of PGF2α for the 
initial 48 h and the extent of adipogenesis was determined at day 8 by either ORO 
staining (C) or immunoblotting for the expression of PPARγ and ERK as a control for 
equal loading (D). Results are representative of three independent experiments.  
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Next, to determine whether Nurr1 is involved in the PGF2α-mediated inhibition 
of adipocyte differentiation, we tested whether the ectopic expression of the DN-Nurr1 
mutant was able to rescue cells from the inhibitory effects of PGF2α on adipogenesis. 
We expressed either MSCV-GFP or DN-Nurr1 in 3T3-L1 cells using retroviruses and 
induced these cells to differentiate by the MDI-induced differentiation protocol in the 
presence of increasing concentrations of PGF2α. As shown in Figure 19C, D, the 
differentiation of the control GFP-expressing cells was inhibited by PGF2α in a 
concentration-dependent fashion as evidenced by the decreased ORO staining and the 
decreased expression of PPARγ. Conversely, we observed a partial rescue of 
differentiation in DN-Nurr1 expressing cells at the concentration of PGF2α that clearly 
inhibited differentiation of control GFP expressing cells, which is evident from the 
increased ORO staining and the increased expression of PPARγ (Fig. 19C, D) These 
results demonstrate that Nurr1 is indeed required for mediating the inhibitory effects of 
PGF2α on adipogenesis. 
 
5.3 Nurr1-mediated inhibition of adipogenesis requires its direct DNA binding: The 
over expression of Nurr1 has previously been shown to inhibit adipocyte differentiation 
(Chao et al., 2008). Hence, we decided to use Nurr1-WT as a positive control in our 
experiments. Similar to the previous findings, the ectopic expression of Nurr1-WT 
inhibited adipogenesis, which is evidenced by the decreased ORO staining and the 
decreased expression of PPARγ (Fig. 20C, D). Furthermore, the ectopic expression of  
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FIGURE 20. Ectopic expression of Nurr1 inhibits adipogenesis via a DNA binding 
and RXR-independent mechanism.  
 
(A) Schematic model showing the Nurr1 mutants and their ability to bind to either DNA 
or RxR. (B) 3T3-L1 preadipocytes were infected with either MSCV-GFP, Nurr1-WT, 
Nurr1-AA or Nurr1-KLL encoding retroviruses and their expression was determined by 
immunoblotting with an antibody specific for Nurr1, while equal protein loading was 
confirmed by immunoblotting with a control antibody directed against ERK. (C, D) Two-
day post-confluent cells were induced to differentiate by the standard MDI-induced 
protocol. After 8 days, adipocyte differentiation was assessed by ORO staining (C) and 
immunoblotting for the expression of PPARγ, aP2 and ERK as a control for equal loading 
(D). (E) 3T3-L1 cells were initially infected with either MSCV-GFP or Nurr1-WT 
encoding retroviruses and then super-infected with either MSCV-Ds-Red or MSCV-Ds-
Red-PPARγ encoding retroviruses, as indicated. Two-day post-confluent cells were 
induced to differentiate by standard MDI-induced differentiation protocol. After 8 days, 
the adipogenesis was determined by ORO staining. Results in (B, C & D) are 
representative of four independent experiments, whereas results in (E) are representative 
of two independent experiments. 
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PPARγ in these cells was able bypass the inhibitory effect of Nurr1-WT on adipogenesis 
(Fig. 20E). Taken together, these results demonstrate that Nurr1 is sufficient to inhibit 
adipocyte differentiation, most likely by a mechanism that is proximal to the expression 
of pro-adipogenic transcription factor, PPARγ.  
Having shown that Nurr1 expression is sufficient to inhibit adipogenesis and 
plays a role in mediating the inhibitory effect of PGF2α on adipocyte differentiation, we 
decided to gain insights into the mechanism by which Nurr1 mediates its inhibitory effect 
on adipogenesis. Being a transcription factor, Nurr1 most commonly regulates gene 
expression by directly binding to DNA (Lammi et al., 2004; Sakurada et al., 1999). 
However, Nurr1 has recently been shown to indirectly transrepress gene expression by 
interacting with DNA-bound NFκB and promoting the recruitment of transcriptional co-
repressor complex (Saijo et al., 2009). Hence, in order to determine whether Nurr1 
interacts directly or indirectly with DNA to inhibit adipogenesis, we took advantage of 
the previously well-characterized mutant form of Nurr1 that is unable to bind the DNA, 
Nurr1-AA with C280A and E281A mutations in DNA binding domain (Fig.20A) (Saijo 
et al., 2009). We expressed this mutant in 3T3-L1 cells by retroviral transduction system 
and initially determined that this mutant was expressed to a level comparable to that of 
Nurr1-WT expression (Fig.20B). Then, we induced these cells to undergo adipogenesis 
with the standard MDI-induced differentiation protocol. As shown in Figure 20C, D, 
while Nurr1-WT expression inhibited adipogenesis as described earlier, Nurr1-AA 
expressing cells completely differentiated into mature adipocytes as evidenced by the 
increased ORO staining and the increased expression of adipocyte specific genes PPARγ 
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and aP2. This shows that the ability of Nurr1 to inhibit adipocyte differentiation is strictly 
dependent upon its ability to directly bind to DNA.  
 
5.4 Nurr1-mediated inhibition of adipogenesis does not require its 
heterodimerization with RXR: Nurr1 is known to regulate gene expression as 
monomer, homodimer or heterodimer with RXR (Maxwell and Muscat, 2006). Hence, to 
determine whether the heterodimerization of Nurr1 with RXR is required to inhibit 
adipogenesis, we took advantage of the previously well-characterized mutant form of 
Nurr1 that cannot heterodimerize with RXR, Nurr1-KLL with K555A, L556A and 
L557A mutation (Fig.20A) (Aarnisalo et al., 2002). We expressed the Nurr1-KLL mutant 
in 3T3-L1 cells and initially determined that it was expressed to a comparable level to 
that of Nurr1-WT expression (Fig.20B). When these cells were induced to undergo 
adipogenesis with MDI, similar to Nurr1-WT expressing cells, Nurr1-KLL expressing 
cells failed to differentiate into mature adipocytes, which is evident from the decreased 
ORO staining and the decreased expression of PPARγ and aP2 (Fig. 20C, D).  This 
demonstrates that Nurr1 does not require its heterodimerization with RXR to inhibit 
adipocyte differentiation.  
 
5.5 CREB and its association with CRTC2 are required for PGF2α-mediated Nurr1 
expression during adipocyte differentiation: Having shown that Nurr1 is induced by 
the PGF2α/calcineurin-signaling pathway and plays a role in mediating the inhibitory 
effect of PGF2α on adipogenesis, we next sought to determine the signaling mechanism  
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FIGURE 21. PGF2α induces Nurr1 expression through CREB-dependent 
mechanism during adipogenesis.  
 
 
3T3-L1 cells transduced with either MSCV-GFP, K-CREB or CREB R314A encoding 
retroviruses were induced to undergo differentiation with MDI in the presence or absence 
of PGF2α (25 nM) and mRNA was collected at 48 h post-induction. Nurr1 expression 
was determined by qRT-PCR. The data is shown as mean ± SEM (one-way ANOVA 
followed by Bonferroni post hoc test; p<0.05; n=3). Results are representative of two 
independent experiments.  
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by which Nurr1 expression is regulated by this pathway. In this regard, the Nurr1 
promoter contains a CREB responsive element (CRE) and has been shown to be 
regulated by the CREB transcription factor in different cell types (Ji et al., 2012; McEvoy 
et al., 2002; Zhao et al., 2011). Interestingly, the CREB-induced Nurr1 expression is 
selectively regulated by a recently identified transcriptional co-activator, CRTC2 
(Conkright et al., 2003). More importantly, CRTC2 is dephosphorylated and activated by 
the calcineurin phosphatase and then, it translocates into the nucleus and regulates the 
CREB transcriptional activity (Screaton et al., 2004). Hence, we sought to determine 
whether CREB and its association with CRTC2 are required for PGF2α to induce Nurr1 
expression. To determine this, we took advantage of two well-characterized CREB 
mutants, K-CREB that blocks DNA binding of endogenous CREB and CREB R314A 
that blocks the direct interaction of CREB with CRTC2 (Walton et al., 1992; Xu et al., 
2007). Thus, K-CREB prevents induction of CREB regulated genes and CREB R314A 
blocks the expression of CRTC2-regulated CREB-induced genes. We introduced either 
control MSCV-GFP or the CREB mutants independently by retroviral transduction into 
3T3-L1 cells and induced these cells to differentiate with MDI in the presence or absence 
of PGF2α. At 48 h post-induction, mRNA was collected to determine the Nurr1 
expression by qRT-PCR. As shown in Figure 21, while PGF2α significantly increased the 
expression of Nurr1 in control GFP expressing cells, ectopic expression of either           
K-CREB or CREB R314A significantly attenuated the PGF2α-induced Nurr1 expression 
during the early stages of adipogenesis. These results demonstrate that CREB, and more 
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specifically, its interaction with CRTC2 are required for the PGF2α-induced Nurr1 
expression during adipocyte differentiation. 
 
5.6 The PGF2α/calcineurin-signaling pathway induces the activation and nuclear 
translocation of CRTC2 co-activator during adipogenesis: Since calcineurin is known 
to activate CRTC2 and the CREB mutant that cannot interact with CRTC2 blocks the 
PGF2α-induced Nurr1 expression, we decided to determine whether the 
PGF2α/calcineurin-signaling pathway induces the activation and nuclear translocation of 
CRTC2 during adipogenesis. Initially, we attempted to determine the activation of the 
endogenous CRTC2 protein using a variety of commercially available antibodies. 
However, due to the poor quality of antibodies, we were unable to successfully determine 
the activation of the endogenous CRTC2. Hence, we used an YFP tagged CRTC2 to 
detect it’s activation by this pathway using immunofluorescence method.  We expressed 
the YFP-CRTC2 in 3T3-L1 cells using retroviruses and induced these cells to undergo 
adipocyte differentiation with MDI in the presence or absence of PGF2α or pretreatment 
with the calcineurin inhibitor, CsA. As shown in Figure 22A and B, MDI alone induced a 
transient cytoplasmic to nuclear translocation of YFP-CRTC2 during the very early stage 
of adipocyte differentiation. In contrast, PGF2α induced a sustained nuclear translocation 
of YFP-CRTC2 for a prolonged period of time. This sustained translocation of CRTC2 
into the nucleus by PGF2α was abolished by the pretreatment with a calcineurin 
inhibitor, CsA. This demonstrates that PGF2α induces a sustained cytoplasmic to nuclear  
 
115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 22. The PGF2α/calcineurin-signaling pathway induces sustained activation 
of CRTC2.  
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(A, B) 3T3-L1 preadipocytes transduced with YFP-CRTC2 encoding retrovirus was 
induced to differentiate with MDI in the presence of either vehicle, PGF2α (25 nM) alone 
or PGF2α (25 nM) plus CsA (1 µg/ml). The nuclear translocation of YFP-CRTC2 was 
determined by immunofluorescence at the indicated time points (A) and the percentage of 
cells with nuclear YFP-CRTC2 was calculated (B). The data is shown as mean ± SEM 
(One-way ANOVA followed by Bonferroni post hoc test; p<0.05; n=3). Results are 
representative of three independent experiments. 
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translocation of CRTC2 co-activator through a calcineurin-dependent pathway during 
adipogenesis. 
5.7 PGF2α requires the CRTC proteins to induce Nurr1 expression during 
adipogenesis: Having shown that CRTC2 co-activator is activated by the 
PGF2α/calcineurin-signaling pathway, we next sought to determine whether CRTC2 is 
indeed required for PGF2α to induce Nurr1 expression during adipogenesis. Hence, we 
attempted to stably deplete the expression of CRTC2 by shRNA approach. Initially, we 
expressed either control shLUC or CRTC2 shRNA in 3T3-L1 cells using retroviruses and 
collected mRNA from the confluent cells to determine the knockdown efficiency of the 
shRNA by qRT-PCR. As shown in Figure 23A, the expression of CRTC2 was 
significantly inhibited by the CRTC2 shRNA. Unexpectedly, this shRNA also inhibited 
the expression of another family member, CRTC1 due to the fact that this shRNA 
partially recognizes the CRTC1 mRNA (Fig. 23C). Next, we determined the expression 
of Nurr1 in these cells in response to PGF2α during adipogenesis. As shown in Figure 
23C, the control shLUC and CRTC2 shRNA expressing cells were induced to 
differentiate with MDI-induced differentiation protocol in the presence or absence of 
PGF2α and mRNA was collected at 48 h post-induction for qRT-PCR. As expected, 
while Nurr1 expression was significantly increased in response to PGF2α in control 
shLUC cells, the stable depletion of CRTC expression significantly attenuated Nurr1 
expression in response to PGF2α. This demonstrates that CRTC proteins are required for 
the PGF2α-induced Nurr1 expression during adipocyte differentiation.  
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FIGURE 23. CRTC co-activators are required for the PGF2α to induce Nurr1 
expression during adipocyte differentiation.  
 
 
(A, B) 3T3-L1 cells infected with either control shLUC or CRTC2 shRNA encoding 
retroviruses were induced to differentiate with MDI in the presence or absence of PGF2α 
(25 nM) and the mRNA was collected at 0 and 48 h post-induction. The shRNA-specific 
 
 
C. 
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knockdown efficiency at 0 h (A) and Nurr1 expression at 48 h post-stimulation (B) were 
determined by qRT-PCR. The data is shown as mean ± SEM (either student’s t test or 
one-way ANOVA followed by Bonferroni post hoc test; p<0.05; n=3). Results are 
representative of two independent experiments. (C) Necleotide alignment of CRTC2 
shRNA with the coding sequences of CRTC2 and CRTC1. 
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5.8 CRTC2 activity is sufficient to induce Nurr1 expression and to inhibit adipocyte 
differentiation: Having shown that CRTC2 is activated by PGF2α and CRTC proteins 
are required for the PGF2α-induced Nurr1 expression, we decided to determine whether 
CRTC2 is sufficient to induce Nurr1 expression in differentiating 3T3-L1 cells. Hence, 
we generated a constitutively active CRTC2 (caCRTC2) by mutating the critical serine 
residues required for its cytoplasmic retention to alanine (S171A and S275A). Then, the 
caCRTC2 was fused to the hormone binding domain of estrogen receptor (ER-caCRTC2; 
Figure 24A), thereby CRTC2 activity can be conditionally activated in response to 
tamoxifen. First, as described in the materials and methods, we determined the 
conditional activation of ER-caCRTC2 by transient transfection luciferase reporter assay 
in HEK293T cells using a well characterized CREB reporter, CRE-Luc. As shown in 
Figure 24B, while luciferase activity was minimal in control GFP and untreated ER-
caCRTC2 cells, tamoxifen treatment was able to significantly induce the luciferase 
activity in ER-caCRTC2 expressing cells. This shows that ER-caCRTC2 is functional 
and its activity can be selectively regulated by tamoxifen. Next, to determine whether the 
conditional activation of CRTC2 is sufficient to induce Nurr1 expression, we expressed 
either MSCV-GFP or ER-caCRTC2 in 3T3-L1 cells using retroviruses and induced these 
cells to differentiate using MDI in the presence or absence of tamoxifen. At 48 h post-
induction, mRNA was collected to determine the Nurr1 expression by qRT-PCR. As 
shown in Figure 24C, Nurr1 was not induced by tamoxifen treatment in control GFP 
expressing cells. In contrast, Nurr1 expression was significantly increased in ER-
caCRTC2 cells in the presence of tamoxifen compared to MDI alone. This shows that the  
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FIGURE 24. Conditional and selective activation of the constitutively active CRTC2 
is sufficient to induce Nurr1 expression and to inhibit adipogenesis.  
 
(A) Schematic model showing the tamoxifen inducible, constitutively active CRTC2 
(ER-caCRTC2). (B) HEK293T cells were transfected with ER-caCRTC2 plasmid (400 
ng) along with CRE-Luc (50 ng) and pRG-TK (25 ng) reporter plasmids. After 16 h post-
transfection, cells were treated with tamoxifen and luciferase activity was determined at  
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4 h post-treatment. (C, D & E) 3T3-L1 cells transduced with either GFP or ER-caCRTC2 
retroviruses were induced to differentiate with MDI in the presence or absence of 
tamoxifen (1 µM). At 48 h post induction, mRNA was collected and Nurr1 expression 
was determined by qRT-PCR (C). After 8 days, adipocyte differentiation was determined 
by ORO (D) and immunobloting for the expression of PPARγ, aP2 and ERK as a loading 
control for equal loading (E). The data is shown as mean ± SEM (One-way ANOVA 
followed by Bonferroni post hoc test; p<0.05; n=3). Results are representative of three 
independent experiments.  
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selective activation of CRTC2 is sufficient to induce Nurr1 expression during 
adipogenesis.  
Next, having demonstrated that the activation of ER-caCRTC2 is sufficient to 
induce Nurr1 expression, we also determined whether the activation of ER-caCRTC2 is 
sufficient to inhibit adipogenesis. Hence, the control GFP or ER-caCRTC2 cells were 
stimulated to undergo adipogenesis with MDI-induced differentiation protocol in the 
presence or absence of tamoxifen for the initial 48 h. As shown in Figure 24D and E, 
control GFP expressing cells differentiated into adipocytes in the presence of tamoxifen. 
In contrast, while ER-caCRTC2 expressing cells differentiated into adipocytes with MDI 
alone, the selective activation of ER-caCRTC2 using tamoxifen inhibited adipogenesis, 
which is evident from the decreased ORO staining and the diminished expression of 
PPARγ and aP2 (Fig. 24D,E). This demonstrates that the selective activation of CRTC2 
is sufficient to inhibit adipogenesis and thus, phenocopies the inhibitory effects of PGF2α 
on adipocyte differentiation. Collectively, our results demonstrate that the sustained 
activation of CRTC2, similar to PGF2α, is sufficient to induce Nurr1 expression and to 
inhibit adipocyte differentiation.  
 
5.9 CRTC co-activator proteins play a critical role in the regulation of normal 
adipocyte differentiation: Having shown that CRTC co-activator proteins, more 
specifically CRTC2, are required for the PGF2α-induced Nurr1 expression and that 
CRTC2 activation is sufficient to inhibit adipogenesis, we next sought to directly 
determine whether CRTC protein is required for the PGF2α-mediated inhibition of  
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FIGURE 25. CRTC is required for normal adipocyte differentiation.  
 
3T3-L1 cells were initially infected with either control shLUC or CRTC2 shRNA 
encoding retroviruses and then super-infected with either Ds-Red or Ds-Red PPARγ 
retroviruses, as indicated. Two-day post-confluent cells were induced to differentiate with 
MDI and adipogenesis was determined after 8 days of induction by ORO (A). (B, C) 
3T3-L1 preadipocytes infected with either control shLUC or CRTC2 shRNA encoding 
retroviruses were induced to differentiate with MDI and  the cell lysates were collected at 
the indicated times after adipogenic stimulation and, immunoblotting was performed for 
C/EBPβ, C/EBPδ, C/EBPα, PPARγ, aP2 and ERK as a loading control.  The results in 
(A) are representative of three independent experiments, whereas the results in (B, C) are 
representative of two independent experiments. 
 
 
 
 
 
 
 
 
 
 
126 
 
 
adipogenesis. To accomplish this, we investigated the ability of CRTC depleted cells to 
differentiate in the presence of PGF2α. We induced either the control shLUC or CRTC2 
shRNA expressing cells to differentiate using MDI-induced differentiation protocol in the 
presence or absence of PGF2α for the initial 48 h. Surprisingly, while control shLUC 
expressing cells completely differentiated into adipocytes, stable depletion of CRTC 
expression inhibited the ability of the cells to undergo adipocyte differentiation in the 
presence of MDI alone, as evidenced by the decreased ORO staining and the decreased 
expression of adipocyte specific genes PPARγ and aP2 (Fig. 25A, B). Hence, we were 
unable to dissect the role of CTRC in mediating the inhibitory effects of PGF2α on 
adipogenesis. However, this provided surprising evidence that the CRTC co-activators 
play a crucial positive regulatory role in the normal adipogenic process. Further, the 
ectopic expression of PPARγ in the CRTC2 shRNA expressing cells rescued their 
potential to differentiate into mature adipocytes (Fig. 25A), suggesting that CRTC 
regulates a critical step(s) proximal to the expression of PPARγ during normal adipocyte 
differentiation process. To further understand the underlying mechanisms, we determined 
the expression of key adipogenic transcription factors in the CRTC2 shRNA expressing 
cells during adipogenesis. As shown in Figure 25B and C, while the expression of the late 
transcription factors, C/EBPα and PPARγ and the early transcription factor, C/EBPβ 
were not affected by the depletion of CRTC protein expression, the expression of the 
early transcription factor C/EBPδ was decreased in these cells, suggesting that CRTC 
proteins might play a critical role in the regulation of C/EBPδ. Collectively, our results 
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demonstrate that CRTC proteins are required for normal adipocyte differentiation process 
and possibly, they regulate the expression of early transcription factor, C/EBPδ.  
 
6. DISCUSSION 
 
In this dissertation chapter, we further investigated the mechanism by which 
PGF2α inhibits adipocyte differentiation and provide evidence that the increased 
expression of Nurr1 plays an important role in mediating the inhibitory effects of the 
PGF2α/calcineurin-signaling pathway on adipogenesis. Further, we have established that 
PGF2α induces Nurr1 expression via the calcineurin-dependent activation of CRTC 
proteins and the subsequent activation of the CREB transcription factor. Collectively, our 
results provide evidence that in addition to the IL-11/gp130/STAT1-signaling pathway 
described in chapter III, PGF2α can also inhibit adipogenesis by the means of a 
calcineurin/CRTC/CREB/Nurr1-dependent signaling mechanism.  
While all the members of the NR4A family of transcription factors are known to 
be transiently expressed in 3T3-L1 cells during the initial few hours of adipogenesis and 
in response to various inflammatory mediators in different cell types (Chao et al., 2008; 
Pei et al., 2005), we found that PGF2α induces a sustained and prolonged expression of 
Nurr1. Interestingly, while PGF2α highly upregulates the expression of Nurr1, other 
family members Nur77 and Nor1 are not induced by PGF2α. More importantly, this 
increased PGF2α-induced Nurr1 expression was completely abrogated to the basal level 
with the inhibition of the calcineurin phosphatase activity, which demonstrates that 
PGF2α induces a sustained expression of Nurr1 via activation of the calcineurin 
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phosphatase. This is consistent with a recent finding in hippocampal neurons 
demonstrating that calcineurin plays an important role in Nurr1 expression in these cells 
(Tokuoka et al., 2014). Thus, our results demonstrate that Nurr1 is a selective 
transcriptional target of the PGF2α/calcineurin-signaling pathway during the early stages 
of adipogenesis. 
While the ectopic expression of Nurr1 has previously been shown to inhibit 
adipocyte differentiation (Chao et al., 2008), we find that the PGF2α/calcineurin-
signaling pathway induces a sustained expression of endogenous Nurr1. Further, the 
transient activation of its family member Nur77 has previously been shown to positively 
regulate adipogenesis, whereas the prolonged ectopic expression of Nur77 has been 
shown to inhibit adipogenesis (Fumoto et al., 2007). In our studies, while PGF2α inhibits 
adipogenesis, it also induces a sustained expression of endogenous Nurr1. Hence, our 
initial hypothesis was that the increased endogenous Nurr1, in addition to IL-11, mediates 
the inhibitory effects of PGF2α on adipogenesis. The direct evidence to support this 
hypothesis came from our observation that the expression of a dominant-negative Nurr1 
was able to partially rescue adipogenesis from the inhibitory effects of PGF2α. This 
shows that the sustained expression of endogenous Nurr1 plays a critical role in 
mediating the inhibitory effects of PGF2α on adipogenesis. However, the mechanism by 
which Nurr1 inhibits adipogenesis and how the dominant-negative Nurr1 functions to 
rescue adipogenesis is unclear. It is possible that the dominant-negative Nurr1 binds to 
DNA and blocks the interaction of the endogenous Nurr1 to DNA. Alternatively, the 
dominant-negative Nurr1 may dimerize with the endogenous Nurr1, bind to DNA and 
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block gene expression through its KRAB repressor domain. Since, we observe a partial 
rescue from PGF2α by expressing the dominant-negative Nurr1 with KRAB repressor 
domain, we predict that most likely the dominant-negative Nurr1 acts to prevent the 
expression of a gene(s) that is induced by the sustained expression of endogenous Nurr1. 
In this respect, Nurr1 has been shown to induce the cell cycle inhibitor p18 and inhibit 
the proliferation of the haematopoietic stem cells (Sirin et al., 2010). However, while 
there is a possibility that Nurr1 could inhibit adipogenesis by blocking the mitotic clonal 
expansion by the similar mechanism, our previous studies demonstrate that PGF2α does 
not inhibit mitotic clonal expansion (Liu and Clipstone, 2007). Hence, we feel that Nurr1 
might induce some other anti-adipogenic gene or microRNA to inhibit adipocyte 
differentiation.  In contrast, since Nurr1 has also been shown to repress gene expression 
in multiple cell types (Jacobs et al., 2009; Kim et al., 2013), it is also possible that Nurr1 
may also directly repress the expression of critical genes involved in adipogenesis.  
 Having provided evidence that Nurr1 is induced and plays a role in mediating the 
inhibitory effects of the PGF2α/calcineurin-signaling pathway on adipogenesis, we were 
then interested to understand the potential mechanisms by which Nurr1 inhibits 
adipogenesis. Nurr1 has been shown to regulate gene expression as either monomer, 
homodimer or as a heterodimer with its partner protein RXR (Maxwell and Muscat, 
2006). Initially, the heterodimerization of Nurr1 with RXR has caught our attention, as 
the master regulator of adipogenesis PPARγ also requires RXR to induce gene expression 
(Palmer et al., 1995). Thus, it raised a possibility that the sequestration of RxR by Nurr1 
might inhibit the availability of RXR to PPARγ, thereby adipogenesis is inhibited due to 
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the blockade of expression of the PPARγ-induced adipocyte specific genes. However, in 
our studies using a Nurr1 mutant that cannot heterodimerize with RXR, we found that 
this mutant is still able to inhibit adipogenesis. This suggests that Nurr1 does not require 
its interaction with RXR to inhibit adipocyte differentiation and RXR is not sequestrated. 
Further, Nurr1 is typically considered as a positive transcription factor and has been 
shown to regulate gene expression through its direct interaction with DNA (Davies et al., 
2005; Lammi et al., 2004; Sakurada et al., 1999). However, the recent findings 
demonstrate that Nurr1 can also regulate gene expression without a direct interaction with 
DNA by binding to the DNA bound NF-κB and subsequent recruitment of repressor 
complex (Saijo et al., 2009). Hence, to delineate whether Nurr1 needs to bind to DNA or 
not to inhibit adipogenesis, we used a mutant Nurr1 that cannot directly bind to DNA. 
While the wild type Nurr1 inhibited adipogenesis, the Nurr1 mutant that cannot bind to 
DNA was unable to inhibit adipogenesis. This provided evidence that Nurr1 must directly 
bind to DNA in order to mediate its inhibitory effects on adipogenesis. However, the 
genes directly regulated by Nurr1 during adipocyte differentiation are not known. 
Collectively, our results provide evidence that while Nurr1 needs to directly bind to DNA 
to inhibit adipogenesis, its heterodimerization with RXR is dispensable to mediate its 
inhibitory effect on adipogenesis.   
Having demonstrated that PGF2α induces Nurr1 expression through activation of 
the calcineurin phosphatase, we focused on the mechanism by which the 
PGF2α/calcineurin-signaling induces Nurr1 expression. In this respect, Nurr1 the 
promoter contains a CRE consensus binding site and CREB has been shown to directly 
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bind to the Nurr1 promoter, and induce Nurr1 expression in synoviocytes (McEvoy et al., 
2002). Further, inflammatory mediators such as PGE2, TNFα and IL-1β have also been 
shown to induce Nurr1 expression through the CREB transcription factor (Ji et al., 2012; 
McEvoy et al., 2002). Hence, we hypothesized that CREB might be involved in the 
PGF2α-induced Nurr1 expression during adipogenesis. Using two different CREB 
mutants that either block the endogenous CREB activity or cannot interact with its co-
activator CRTC2, we found that CREB and its association with CRTC2 co-activator are 
required for the PGF2α to induce Nurr1 expression during adipogenesis. While blocking 
the calcineurin activity completely inhibits the PGF2α-induced Nurr1 expression, the two 
different CREB mutants that we used in our studies were unable to completely abrogate 
the PGF2α-induced Nurr1 expression. While the inadequate expression of these mutants 
might be a possibility for this incomplete blocked of Nurr1 expression, it is also possible 
that another transcription factor downstream of calcineurin might also be involved in 
regulating Nurr1 expression. In this respect, NF-κB is known to be regulated by 
calcineurin and has been shown to regulate Nurr1 expression in multiple cell types (Ji et 
al., 2012; McEvoy et al., 2002). Hence, it is possible that Nurr1 expression is regulated 
by PGF2α through activation of multiple transcription factors downstream of calcineurin. 
Nevertheless, our findings demonstrate that CREB plays an important role in the PGF2α-
induced Nurr1 expression during adipogenesis. 
Having established that CREB is involved in the PGF2α-induced Nurr1 
expression, we focused on the direct link between calcineurin and CREB in the regulation 
of Nurr1 expression. It is well-known that CREB activity is regulated by CRTC co-
132 
 
 
activator proteins and importantly, these co-activators are dephosphorylated, and 
activated by calcineurin phosphatase (Screaton et al., 2004). Further, CRTC2 is known to 
selectively regulate CREB-induced Nurr1 expression in multiple cell types (Conkright et 
al., 2003). In addition, we found that the CREB mutant that cannot interact with CRTC2 
was able to significantly inhibit the PGF2α-induced Nurr1 expression, thus providing 
initial evidence for the role of CRTC2 in the regulation of Nurr1 expression.  Initially, 
using YFP tagged CRTC2, we found that PGF2α induces a sustained activation and 
nuclear translocation CRTC2, whereas this sustained activation was completely blocked 
by pretreatment with calcineurin inhibitor, CsA. Thus, we found that the 
PGF2α/calcineurin-signaling causes a sustained activation of the CRTC2 co-activator 
during adipocyte differentiation. Interestingly, MDI treatment alone caused a transient 
nuclear translocation of CRTC2, although the functional significance of this early 
transient activation of CRTC2 is not known. Having established that CRTC2 is activated 
by the PGF2α/calcineurin-signaling, we directly determined its role in Nurr1 expression 
using a shRNA-mediated knockdown approach. We found that the depletion of the 
endogenous CRTC proteins abrogated the PGF2α-induced Nurr1 expression, thereby 
providing evidence that CRTC proteins are required for the PGF2α-induced Nurr1 
expression during adipogenesis. Further, the selective activation of a tamoxifen inducible 
form of a constitutively active CRTC2 was sufficient to induce Nurr1 expression and also 
inhibits adipogenesis. This demonstrates that CRTC2 activation is sufficient to induce 
Nurr1 expression and to inhibit adipogenesis. Collectively, we provide evidence that  
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FIGURE 26. Schematic model showing that the PGF2α/calcineurin-signaling 
pathway induces Nurr1 expression via CRTC2/CREB transcriptional complex to 
inhibit adipogenesis.  
 
 
The PGF2α/calcineurin-signaling pathway activates CRTC2 co-activator, which in turn 
activates CREB transcription factor. The CRTC2/CREB transcriptional complex induces 
Nurr1 expression, which inhibits adipocyte differentiation. 
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CRTC proteins are required for the PGF2α-induced Nurr1 expression and CRTC2 is 
sufficient to induce Nurr1 expression.  
Though the selective activation of CRTC2 inhibits adipogenesis and CRTC2 
plays a crucial role in mediating the inhibitory effects of PGF2α on adipocyte 
differentiation, surprisingly, we observed that the stable depletion of CRTC expression 
using the shRNA approach also blocks the normal adipocyte differentiation process. 
When we determined the expression of key adipogenic transcription factors, we observed  
that the expression of C/EBPδ, an early adipogenic transcription factor, is substantially 
decreased in CRTC2 shRNA expressing cells. This is consistent with the previous finding 
that CRTC2 is recruited to the C/EBPδ promoter to regulate CREB-dependent induction 
of C/EBPδ (Hallenborg et al., 2012). Further, we also observed that CRTC2 is transiently 
translocated into the nucleus in response to MDI (Fig. 22A, B), which correlated with the 
time of expression of C/EBPδ expression during adipogenesis. Thus, we predict that the 
early transient activation of CRTC2 positively regulates adipogenesis by potentially 
regulating C/EBPδ expression. Conversely, the PGF2α/calcineurin-signaling causes a 
sustained activation of CRTC2, resulting in the sustained expression of Nurr1 and 
inhibition of adipocyte differentiation. Thus, it appears that the temporal activation of 
CRTC2 is a switch between its positive and negative effects on adipocyte differentiation. 
 Collectively, we provide evidence that the PGF2α/calcineurin-signaling pathway 
induces Nurr1 expression via activation of the CRTC/CREB transcriptional complex 
during adipogenesis. Moreover, we demonstrate that the sustained expression of 
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endogenous Nurr1 plays a role, atleast in part in mediating the inhibitory effects of the 
PGF2α/calcineurin-signaling pathway on adipogenesis. 
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  CHAPTER V 
SUMMARY AND CONCLUDING COMMENTS
 PGF2α has long been known to be a potent inhibitor of adipocyte differentiation in 
vitro (Casimir et al., 1996; Miller et al., 1996). Moreover, recent studies have indicated 
that PGF2α also functions as an endogenous negative regulator of adipogenesis and plays 
an important role in the regulation of adipose tissue accumulation in vivo, where it 
appears to oppose the development of obesity and its associated co-morbidities (Volat et 
al., 2012). Given this clear critical physiological role of PGF2α in the negative regulation 
of adipose tissue development in vivo, it is of considerable interest to understand the 
underlying molecular mechanisms by which PGF2α regulates the adipogenic process. In 
this regard, our previous studies have demonstrated that PGF2α inhibits adipogenesis 
through a signaling pathway involving the activation of the Gαq-coupled prostanoid FP 
receptor, a subsequent increase in the intracellular calcium and the activation of the 
calcium-dependent phosphatase, calcineurin (Liu and Clipstone, 2007). In this 
dissertation, we have now extended these prior studies and provide evidence that the 
PGF2α/calcineurin-signaling pathway acts to inhibit adipogenesis by inducing the 
expression of the IL-11 cytokine and the Nurr1 nuclear hormone receptor. In the case of 
IL-11, we demonstrate that IL-11 functions in an autocrine/paracrine fashion and induces 
a gp130 co-receptor-dependent activation of the STAT1 transcription factor, which we 
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show is essential for mediating the inhibitory effects of PGF2α on adipogenesis. In the 
case of Nurr1, we show that Nurr1 plays an important role in mediating the inhibitory 
effects of PGF2α on adipogenesis and further, demonstrate that PGF2α induces a 
calcineurin-dependent, sustained activation and nuclear translocation of CRTC proteins, 
which then interact with CREB to drive Nurr1 expression. Collectively, our studies 
provide evidence that the PGF2α/calcineurin-signaling pathway inhibits adipogenesis 
through two independent signaling mechanisms:  
IL-11/gp130/STAT1- and CRTC/CREB/Nurr1-signaling.   
 Although we provide evidence that IL-11 and Nurr1 each independently mediate 
the inhibitory effects of PGF2α on adipogenesis, it is noteworthy that neither depletion of   
IL-11 and STAT1 using shRNAs, nor blocking the endogenous Nurr1 activity with a 
dominant-negative Nurr1 were able to completely rescue the differentiation of 3T3-L1 
preadipocytes in the presence of PGF2α. These findings contrast with our prior results 
demonstrating that the inhibition of calcineurin is able to essentially fully abrogate the 
anti-adipogenic effects of PGF2α (Liu and Clipstone, 2007). While in part these 
differences may be explained by incomplete knockdown of STAT1 and IL-11 or 
incomplete expression of dominant-negative Nurr1, as well as potentially the non-cell 
autonomous actions of the IL-11 cytokine, we feel that it is likely that both the IL-11 and 
Nurr1 pathways function together collaboratively to mediate the inhibitory effects of 
PGF2α on adipogenesis. Further, we have previously reported that activation of the 
PGF2α/calcineurin-signaling pathway in differentiating 3T3-L1 preadipocytes also 
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induces the HIF-1-dependent expression of DEC1 (Liu and Clipstone, 2008), a 
transcriptional repressor that is known to inhibit adipocyte differentiation by preventing 
the expression of PPARγ2 (Yun et al., 2002). Hence, it appears that calcineurin functions 
as a central node for mediating the inhibitory effects of PGF2α by activating multiple 
signaling pathways that ultimately collaborate together to effectively inhibit the 
adipogenic process. 
 While we demonstrate that exogenous PGF2α acts through calcineurin to inhibit 
adipogenesis (Liu and Clipstone, 2007), our previous studies showed that blocking the 
endogenous calcineurin activity enhanced the adipogenic potential of preadipocytes and 
thus, suggested that calcineurin acts as an endogenous negative regulator of adipocyte 
differentiation (Neal and Clipstone, 2002). Likewise, PGF2α is transiently synthesized 
during the very early stage of adipogenesis (Fujimori et al., 2010a) and inhibiting its 
endogenous synthesis has been shown to enhance adipose tissue development in vivo 
(Volat et al., 2012). Thus, PGF2α also functions as endogenous inhibitor of adipose 
tissue development. Hence, it is tempting to speculate that the endogenous inhibitory 
effect of PGF2α is also mediated through calcineurin-dependent activation of the 
signaling pathways described in this dissertation. In this regard, we find an endogenous, 
calcineurin-dependent secretion of IL-11 during the early stages of normal adipogenesis. 
Further, inhibiting IL-11 signaling using either a dominant-negative gp130 or depleting 
its downstream effector STAT1, enhances the efficiency of preadipocytes to differentiate 
into mature adipocytes. Hence, we predict that the endogenous inhibitory effect of the 
PGF2α/calcineurin-signaling pathway is, at least in part, mediated through activation of 
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an autocrine/paracrine feedback loop involving IL-11/gp130/STAT1-signaling. In 
addition, we find that the PGF2α/calcineurin-signaling also activates other signaling 
pathways including the expression Nurr1 and DEC1, which mediate the inhibitory effects 
of exogenous PGF2α. Although we do not currently have any direct evidence to support 
their role in mediating the inhibitory effects of endogenous PGF2α on adipogenesis, we 
cannot exclude their potential endogenous role and further studies are needed.  
 Multiple lines of evidence show that adipose tissue expansion through de novo 
generation of new adipocytes play a protective role from the development of obesity-
associated complications by increasing the lipid buffering capacity of adipose tissue and 
preventing lipotoxicity (Tan and Vidal-Puig, 2008; Virtue and Vidal-Puig, 2010). In this 
regard, PGF2α is known to restrict adipose tissue expansion in vivo, which results in the 
development of obesity-associated consequences such as insulin resistance (Volat et al., 
2012). In our studies, we find that calcineurin functions as a central node to mediate the 
inhibitory effects of PGF2α on adipogenesis. Hence, it is tempting to ask whether 
inhibiting calcineurin activity in vivo specifically in preadipocytes or adipose tissue with 
clinically available calcineurin inhibitors would enhance adipogenesis, thereby increasing 
the lipid buffering capacity and providing beneficial effects to obese patients. In this 
respect, organ transplanted patients who are treated with calcineurin inhibitors to prevent 
graft rejection are known to develop obesity (LaGuardia and Zhang, 2013). Given our 
finding that blocking endogenous calcineurin activity enhances adipogenesis (Neal and 
Clipstone, 2002), it is possible that these patients develop excessive adipose tissue due to 
increased number of adipocytes. While this effect seems to be beneficial to prevent 
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lipotoxicity, calcineurin activity is required for the growth and proliferation of insulin 
secreting pancreatic β-cells (Heit et al., 2006) and the prolonged use of calcineurin 
inhibitors leads to the development of type 2 diabetes due to dysfunction of pancreatic β-
cells (Drachenberg et al., 1999; Weir and Fink, 1999). Hence, while the prolonged oral 
and parentral administration of calcineurin inhibitors is more deleterious than beneficial, 
the selective tissue specific delivery of these drugs to adipose tissue might have better 
effect with fewer side effects by enhancing adipogenesis and improving metabolic 
complications in obese patients. Alternatively, other signaling pathways described in this 
dissertation that are activated downstream of calcineurin could be used as a potential 
therapeutic target to enhance the adipogenesis.   
 Finally, while our studies demonstrate that STAT1 and Nurr1 proteins function as 
downstream effectors of the PGF2α/calcineurin-signaling, the precise molecular 
mechanism by which they inhibit adipocyte differentiation is not known. Since, these two 
proteins are known to directly regulate gene expression both positively and negatively 
(Furukawa et al., 2009; Jacobs et al., 2009; Kim et al., 2013; Liu et al., 2008; Ramana et 
al., 2000; Sirin et al., 2010), we predict that they likely inhibit adipogenesis by 
influencing the expression of genes involved in the adipogenic process. In a simple 
model, both STAT1 and Nurr1 might directly repress the expression of the key 
adipogenic transcription factor, PPARγ, thereby inhibiting adipogenesis. In this respect, 
STAT1 has previously been shown to directly bind to the PPARγ promoter in vitro 
(Hogan and Stephens, 2001). Further, STAT1 is known to interact with co-repressors and 
inhibit gene expression (Kamitani et al., 2008; Liu et al., 2001). Hence, we predict that 
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STAT1 could potentially directly bind to the PPARγ promoter, recruit transcriptional co-
repressors and inhibit PPARγ expression. In the case of Nurr1, another related nuclear 
hormone receptor COUP-TFII has been shown to directly bind to the PPARγ locus, 
where it recruits co-repressor complexes and inhibits adipogenesis (Okamura et al., 
2009). Further, Nurr1 has also been shown to interact with co-repressors and inhibit gene 
expression (Kim et al., 2013; Saijo et al., 2009). Hence, similar to STAT1, it is possible 
that Nurr1 could directly bind to the PPARγ promoter, recruit co-repressor and inhibit the 
expression of PPARγ. In contrast to directly inhibiting the expression of key adipogenic 
transcription factors, it is possible that both STAT1 and Nurr1 might indirectly inhibit 
adipogenesis by increasing the expression of a gene(s) that itself directly inhibits the 
expression of key adipogenic transcription factors and thereby, inhibits adipogenesis. 
However, our microarray analysis did not identify any potential candidate genes. Another 
possibility is that both STAT1 and Nurr1 could upregulate the expression of a 
microRNA(s) that inhibits the expression of the key adipogenic transcription factors, 
PPARγ or C/EBPα. In this regard, it is interesting to note that STAT1 has recently been 
implicated in promoting the expression of microRNA-27a (Wang et al., 2010), a 
mircoRNA that has previously been shown to negatively regulate the expression of the 
PPARγ mRNA and block adipogenesis when overexpressed in 3T3-L1 preadipocytes 
(Kim et al., 2010). However, whether this microRNA is induced by STAT1 in response 
to PGF2α during adipogenesis is not known and thus, requires further studies. While 
there are multiple possible mechanisms by which STAT1 and Nurr1 could potentially 
inhibit adipogenesis, the critical genes involved have not been identified. 
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FIGURE 27. Schematic model showing the signaling pathways involved in mediating 
the inhibitory effects of PGF2α on adipogenesis.  
PGF2α activates the calcium-dependent phosphatase calcineurin via activation of Gαq 
coupled FP prostanoid receptor. Then, the PGF2α/calcineurin-signaling pathway induces 
the expression of the IL-11 cytokine, which activates STAT1 transcription factor via 
gp130 co-activator to inhibit adipogenesis. Further, the PGF2α/calcineurin-signaling 
pathway also activates CRTC/CREB transcriptional complex and subsequently, induces 
the expression of the orphan nuclear hormone receptor, Nurr1 to inhibit adipocyte 
differentiation. Collectively, both IL-11 and Nurr1 function downstream of the 
PGF2α/calcineurin-signaling pathway to exert its inhibitory effects on adipogenesis. 
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The identification of the direct in vivo targets of Nurr1 and STAT1 will require the use of 
modern, high throughput techniques such as ChIP-sequencing.  
 In summary, the work of this dissertation has afforded novel insights into the 
molecular mechanisms underlying the anti-adipogenic effects of the PGF2α/calcineurin-
signaling pathway and has provided evidence for the potential role of the IL-11 cytokine 
and the Nurr1 orphan nuclear hormone receptor in mediating the inhibitory effects of 
PGF2α on adipocyte differentiation. Thus, our studies significantly expanded our 
understanding concerning the molecular mechanisms involved in the PGF2α-mediated 
inhibition of adipogenesis. 
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